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ABSTRACT

Sleep apnea (SA) affects as many as 20% of the adult population in the United
States. It elicits intermittent hypoxia (IH) and causes pulmonary hypertension (PH),
however the mechanisms of this PH have not been well studied. IH has been shown to
cause polycythemia, pulmonary vascular remodeling and increases in vasoconstrictor
reactivity. CO2 supplementation may be protective in the development of PH, therefore
we assessed effects of IH with and without CO2 supplementation on indices of PH and
pulmonary vasoconstrictor reactivity.

IH with CO2 supplementation resulted in

eucapnic IH (E-IH) and the lack of polycythemia or vascular remodeling. However, EIH caused significant right ventricular hypertrophy and increased pulmonary
vasoconstrictor reactivity, which was mediated by vascular smooth muscle (VSM) Ca2+
sensitization. We, therefore, sought to determine the mechanism of this enhanced
vasoconstrictor reactivity by assessing vasoconstriction and VSM Ca2+ responses to the
endothelium-derived vasoconstrictor peptide endothelin-1 (ET-1). Given evidence that
Rho kinase (ROK), PKC and reactive oxygen species (ROS) contribute to the
development of PH, we addressed their respective contributions to augmented
pulmonary vasoconstrictor reactivity to ET-1 following E-IH. Interestingly, we found
that ROK did not contribute to ET-1-induced pulmonary vasoconstriction. However,

v

PKC- and ROS- dependent signaling is augmented following E-IH and these mediators
appear to signal in series, with the mitochondria providing the source of ROS.
Furthermore, E-IH augments PKCα/β-dependent ROS generation.

Therefore, both

mitochondrial ROS and PKCα/β represent potential therapeutic targets in the
development of SA-induced PH.
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CHAPTER I

INTRODUCTION
Sleep apnea (SA) is a disorder with increasing prevalence in the United States,
affecting at least 4% of the adult population and as many as 20% of adults age 65 and
older (Young et al., 1993). SA causes intermittent hypoxia (IH) and arterial hypoxemia.
Recently, it has been appreciated that SA patients and animals exposed to IH develop
pulmonary hypertension (PH), but the mechanism by which this occurs is poorly
understood. In well studied models of PH, such as chronic hypoxic (CH) PH, there is
increased pulmonary vascular resistance caused by active vasoconstriction, pulmonary
arterial remodeling and possibly increased blood viscosity due to polycythemia. The
severity of PH may be greatly affected by the contractility of pulmonary vascular smooth
muscle (VSM), particularly in the small arteries. Although previous studies indicate that
IH increases pulmonary vasoconstrictor reactivity (Thomas & Wanstall, 2003), the
mechanism by which this occurs has not been characterized. VSM tone is regulated by
changes in VSM intracellular Ca2+ ([Ca2+]i) and sensitivity of the contractile apparatus to
changes in [Ca2+]i. The following sections outline the conditions associated with IH, the
development of PH and mechanisms of VSM cell contraction.

Sleep Apnea
Sleep apnea (SA) occurs when a person’s breathing is interrupted during sleep
and is classified as either obstructive, central or a mixture of both. In the case of
obstructive SA, a physical collapse of the upper airway occurs because of a relaxation of
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the muscles which support the soft tissues of the throat, stopping airflow for >10 seconds.
Risk factors for obstructive SA include obesity, large neck circumference, and smoking
(Young et al., 2002). Central SA occurs because of a lack of central nervous respiratory
drive during sleep, and risk factors include being male, suffering from brain tumor or
stroke and congestive heart failure (Eckert et al., 2007;Mayo Clinic, 2009). A patient
experiences significant SA when there are more than 5 apneic or hypopneic episodes per
hour of sleep as measured by the respiratory disturbance index (Mohsenin, 2001). This
condition is characterized by many arousals from sleep and a fall in arterial O2 saturation
(hypoxemia). Most patients suffer from daytime sleepiness which may impair work
performance and many experience associated cardiovascular diseases (Partinen &
Guilleminault, 1990), such as hypertension, ischemic heart disease and stroke. More
recently, it has been shown that SA is associated with an increased risk of PH, especially
in patients with chronic lung disease (Alchanatis et al., 2001). However, the mechanisms
of SA-induced PH have not been well characterized.

Sleep Apnea- Induced Pulmonary Hypertension.
It has been known for several years that SA increases the incidence of
cardiovascular complications such as heart failure, stroke and systemic hypertension
(Dimsdale et al., 2000;Shahar et al., 2001). However, it is now appreciated that SA also
elicits changes in the pulmonary vasculature and right heart (Sajkov & McEvoy, 2009).
The prevalence of PH in SA has been reported to be between 17% (Chaouat et al.,
1996;Zielinski, 2005) and 43% (Arias et al., 2006;Tilkian et al., 1976). If left untreated,
PH can result in right heart failure and death. Thus, understanding the mechanisms of PH
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associated with SA is crucial to preventing and treating the disease and associated right
heart failure in such patients.
SA causes remarkable acute changes in pulmonary artery pressure (PAP)
(Bonsignore et al., 1994), with PH occurring during apneic episodes (Tilkian et al.,
1976). Marrone et al. found that when measurements were corrected for intrathoracic
pressure swings, transmural PAP increased progressively throughout apneic episodes
(Marrone et al., 1989). In agreement with this study, Schafer and colleagues determined
that systolic transmural PAP increased from ~28 mmHg at the beginning of apnea to ~39
mmHg at the end of an apneic episode, indicating repetitive PH episodes occur during SA
(Schafer et al., 1998). These studies provided evidence for PH in SA patients during
sleep, however they failed to address whether SA was sufficient to cause diurnal
pulmonary hypertension.
Daytime PH has been reported to have a high occurrence in SA patients, however
some studies can not rule out the contribution of underlying lung disease to PH in
patients with SA (Fletcher et al., 1987;Tilkian et al., 1976). In such studies, the patients
had a mixture of SA and chronic obstructive pulmonary diseases (COPD) such as
emphysema and chronic bronchitis (Chaouat et al., 1996;Fletcher, 1990) or obesity,
making it difficult to assess the relative contributions of SA-induced IH and diurnal
hypoxemia secondary to underlying lung disease (Sajkov & McEvoy, 2009). Bradley et
al. studied 50 SA patients and concluded that daytime hypoxemia and/or hypercapnia
were necessary for the development of right heart failure (Bradley et al., 1985).
Consistent with those findings, Chaouat and colleagues reported that permanent daytime
PH was observed in 17% of SA patients and this occurrence was strongly linked to
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hypoxemia (Chaouat et al., 1996). Weitzenblum et al. studied 46 patients and found that
20% of them developed PH, and this was again related to the presence of sustained
hypoxemia (Weitzenblum et al., 1988).

Furthermore, continuous positive airway

pressure (CPAP) lowers PAP in patients suffering from concomitant COPD and SA
(Fletcher, 1990), or so-called “overlap syndrome” (Weitzenblum et al., 2008). These
studies highlight the fact that SA can exacerbate PH in people who suffer from chronic
lung disease.
Whether SA is sufficient to cause PH in the absence of underlying lung disease
has been a subject of recent study. In order to more directly address the role of SA in the
development of PH, patients suffering from SA without any other identifiable
cardiopulmonary disease have been studied. Alcanatis et al. found that ~21 % of SA
patients without any other cardiac or lung disease were pulmonary hypertensive
(Alchanatis et al., 2001). Consistent with these findings, Bady and colleagues found the
existence of PH in 27% of patients with “pure” SA (Bady et al., 2000). These studies
support the idea that SA is an independent risk factor for PH, however diurnal hypoxemia
may contribute to the development of PH.
Apneic episodes during sleep are simulated in rodent models of SA by exposing
animals to frequent cycles of hypoxia/normoxia.

These cycling models range from

exposures of 15 sec- 6 min/cycle carried out 7-12 hr/day over 2-8 weeks (Bertuglia &
Reiter, 2009;Bradford, 2004;Campen et al., 2005;Fagan, 2001;Fletcher et al.,
1995;Nisbet et al., 2008). In addition to developing systemic hypertension, many of
these animals exposed to intermittent hypoxia (IH) show evidence of PH (Bradford,
2004;Campen et al., 2005;Fagan, 2001;Fletcher et al., 1987).
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These models have

included both IH alone (Bradford, 2004;Campen et al., 2005;Fagan, 2001;Nisbet et al.,
2008;Snow et al., 2008), as well as IH combined with supplemental CO2 administration
(Bradford, 2004;Fletcher et al., 1995;Snow et al., 2008), which is intended to mimic the
increase in arterial CO2 during apnea (Borges et al., 2002). Both models are associated
with PH, however CO2 supplementation may blunt the effects of IH, as occurs with CH
(Kantores et al., 2006).
Given the strong evidence that SA can both exacerbate PH due to underlying lung
disease and result in PH in the absence of concomitant lung disease, it is important to
understand the mechanisms by which IH induces PH. The factors which may influence
the development of IH-induced PH by increasing pulmonary vascular resistance are
discussed below.

Hemodynamic Components of Pulmonary Hypertension.
The pulmonary circulation is characterized by low pressure and low resistance
under normoxic conditions. However, under pathological conditions that lead to CH,
vascular resistance is increased by pulmonary arterial vasoconstriction, remodeling and
polycythemia. Pouseuille’s equation describes the factors affecting arterial resistance:
Resistance = 8ηL / πr4
Where L is the length of the tube, η is viscosity and r is the radius of the tube. Although
this equation describes resistance in a straight, rigid tube conducting a homogeneous
fluid, it provides an approximation for factors that determine resistance to flow in blood
vessels.

Based on this relationship, an increase in blood viscosity, as occurs with

polycythemia, would increase resistance. More importantly, however, a decrease in
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radius of the vessel, resulting from vasoconstriction or vascular remodeling, causes a
profound increase in resistance since resistance is inversely proportional to radius to the
fourth power. Based on an ohmic relationship where:

↑ Resistance x Flow = ↑ Δ Pressure

An increase in resistance causes a proportional increase in PAP when flow is maintained
constant. An increase in pressure within the pulmonary circulation places an elevated
work load on the right side of the heart. To compensate for this greater workload, the
right heart undergoes hypertrophy, and if untreated the end result can be right heart
failure and death depending on the severity of PH.

Mechanisms of Pulmonary Hypertension
Polycythemia. Polycythemia is an increase in number of circulating red blood
cells, which occurs as a result of increased erythropoeisis. Erythropoeisis normally
proceeds at low basal levels in order to replace old red blood cells and can be stimulated
by a decrease in number of red blood cells, hypoxia or an increase in the affinity of
hemoglobin for oxygen.

In response to hypoxia, the transcription factors hypoxia-

inducible factor 1 and 2 (HIF-1 and HIF-2) mediate a profound increase in erythropoeitin
synthesis by the fetal liver and adult kidney (Semenza & Wang, 1992;Warnecke et al.,
2004). Erythropoeitin is released from these tissues into the circulation, where it acts on
erythroid progenitor cells in the bone marrow to induce erythropoeisis (Ebert & Bunn,
1999). Thus, polycythemia serves as a compensatory mechanism to facilitate greater
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oxygen carrying capacity of the blood under conditions of decreased oxygen availability,
but the resultant increase in viscosity may contribute to increased pulmonary vascular
resistance under prolonged exposure to hypoxia (Figure 1) (Fried et al., 1983).
An increase in O2 carrying capacity of the blood is beneficial in the setting of SA,
in which acute hypoxemia can occur during apneic episodes. IH has consistently been
shown to elicit polycythemia in the absence of supplemental CO2 (Bertuglia & Reiter,
2009;Bradford, 2004;Campen et al., 2005;Fagan, 2001;McGuire & Bradford, 1999;Snow
et al., 2008). As would be predicted, SA patients have significantly greater hematocrits
than normal subjects, however this is reportedly not in the range of clinical polycythemia
(Choi et al., 2006;Nobili et al., 2000). This finding is not surprising given that apneic
episodes are associated with CO2 retention (Alford et al., 1986), which may blunt the
development of polycythemia as occurs in IH rats (Snow et al., 2008). However,
eucapnia or hypercapnia tend to blunt or prevent the IH-induced polycythemia (Snow et
al., 2008). In contrast, Fletcher et al. found that neither 35 days of eucapnic, hypocapnic
nor hypercapnic IH elicited a change in hematocrit (Fletcher et al., 1995). Given the
discrepant findings regarding IH-induced polycythemia, this study will address changes
in hematocrit in our model of SA.

Vascular Remodeling. Early studies of the pulmonary circulation of high altitude dwellers
emphasized the idea that structural changes in the vascular bed were responsible for CHinduced PH.

Sime et al. found that non-native highlanders develop PH that is
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Intermittent
Hypoxia

Vasoconstriction

Vascular
Remodeling

Polycythemia

Vascular
Resistance
Pulmonary
Hypertension

Figure 1. Intermittent hypoxia may mediate an increase in pulmonary vascular
resistance via vasoconstriction, vascular remodeling or polycythemia, all of which
could contribute to pulmonary hypertension.
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only partially reversed by acute O2 administration, presumably by reversing hypoxic
pulmonary vasoconstriction (Sime et al., 1971). The remaining elevation in PAP was
thought to be related to pulmonary vascular remodeling. The occurrence of CH-induced
pulmonary vascular remodeling was confirmed by studies in CH animals, showing that
small pulmonary arteries became remodeled beginning after only 2 days of hypoxia
(Meyrick & Reid, 1978). There are two general mechanisms by which structural
alterations of the pulmonary vasculature could mediate an increase in pulmonary vascular
resistance: 1) remodeling of the walls of pulmonary resistance arteries to mediate a
decrease in luminal diameter and 2) a decrease in the total number of pulmonary arteries,
a phenomenon referred to as rarefaction (Howell et al., 2004). Arterial remodeling
involves a thickening of the arterial wall, and this may encroach upon the vascular lumen,
increasing pulmonary vascular resistance (Hopkins & McLoughlin, 2002). Specifically,
proliferation and hypertrophy of the smooth muscle and the development of smooth
muscle-like cells in previously non-muscularized vessels of the lung can reduce the
luminal radius and increase vascular resistance.
Many stimuli can result in VSM proliferation, such as increases in VSM [Ca2+]i
(Sweeney et al., 2002a) and receptor-mediated agonists such as endothelin-1 (ET-1)
(Ambalavanan et al., 2007;DiCarlo et al., 1995;Huang et al., 2009), 5-HT (Fanburg &
Lee, 1997) and thromboxanes (Ko, 1997).

Inhibition of Ca2+ influx decreases

proliferation of pulmonary artery smooth muscle cells (PASMCs) from patients with
idiopathic PH (Fujio et al., 2006;Yu et al., 2004), suggesting Ca2+ influx is a potent
stimulus in the development of pulmonary vascular remodeling.
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The endothelium-

derived vasoconstrictor peptide ET-1 stimulates both ETA and ETB receptors on PASMC,
promoting cell proliferation (Davie et al., 2002) and endogenous ET-1 production by the
endothelium likely contributes to the proliferative response under hypoxic conditions.
Hypoxia increases 5-HT production by platelets and neuroepithelial bodies (Esteve et al.,
2007). The increase in 5-HT then facilitates smooth muscle cell (SMC) and fibroblast
(Welsh et al., 2004) mitogenesis via stimulation of 5-HT receptors (Pitt et al., 1994) and
5-HT uptake (Lee et al., 1994) via mechanisms that may involve ROS and stabilization of
HIF-1α (Esteve et al., 2007). In addition, thromboxanes could contribute to PASMC
proliferation (Ko, 1997). Thus, changes in the medial layer of the PA can be triggered by
a number of stimuli, which then contribute to the development of PH. However, it is
additionally possible that proliferation and hypertrophy of pulmonary VSM resulting
from CH do not alter luminal diameter in small pulmonary arteries, as suggested by
studies by Hyvelin and colleagues in CH rats (Hyvelin et al., 2005).
This remodeling, which accompanies PH in many models of the disease, also
involves changes in adventitial and intimal layers of the vessel (Stenmark et al., 2006).
Adventitial thickening due to increased number of fibroblasts and myofibroblasts in the
vessel wall provides a substantial component of vessel wall thickening (Rose et al.,
2002;Short et al., 2004). Endothelial cell proliferation and intimal thickening occur in
models of hypoxic PH but may provide only a minimal contribution to the overall
morphological changes in the vessel wall (Meyrick & Reid, 1980).
The second form of pulmonary arterial remodeling which has also been
implicated in contributing to the development of PH is rarefaction.

A correlation

between rarefaction and PH was observed in cystic fibrosis patients who died from
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complications related to PH (Ryland & Reid, 1975). In addition, Hislop and Reid found
that rats exposed to 14 days of hypobaric hypoxia (380 mmHg) possessed fewer
pulmonary arteries smaller than 200 μm (Hislop & Reid, 1976). This rarefaction would
be expected to decrease the number of parallel pathways for blood flow, and thus
increase vascular resistance (Hislop & Reid, 1976).
Although the above studies of CH-induced PH support a major role for pulmonary
vascular remodeling in CH-induced increases in pulmonary vascular resistance (Sime et
al., 1971), more recent studies suggest that CH causes angiogenesis in the pulmonary
circulation (Howell et al., 2003). In lungs of rats exposed to two weeks of normobaric
hypoxia, stereological studies revealed an increase in total length and volume of
pulmonary vessels. In addition, endothelial surface area and number of endothelial cells
is increased (Howell et al., 2003). These results are consistent with the effects of hypoxia
on systemic vascular beds (Lamanna et al., 1992).

In contrast to rarefaction,

angiogenesis would provide an increase in the number of parallel pathways for blood
flow, thus lowering pulmonary vascular resistance. If this is the case, a larger component
of CH-induced PH must be attributed to vasoconstriction as will be discussed below.
Similar to CH, IH causes pulmonary vascular remodeling. Nisbet et al. found that
mice exposed to 8 weeks of IH (10% O2, 45 cycles/hour, 8 hr/day) had an increase in the
number of SMCs in small pulmonary arteries, a decrease in the luminal radius and an
increase arterial wall thickness (Nisbet et al., 2008). In agreement with this study, we
have shown that 2 week exposure to IH causes an increase in pulmonary arterial wall
thickness in rats (Snow et al., 2008). Furthermore, in mice lacking the gp91phox subunit
of NADPH oxidase, IH-induced pulmonary vascular remodeling is eliminated (Nisbet et
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al., 2008), suggesting that NADPH oxidase-derived superoxide mediates pulmonary
vascular remodeling in IH exposed mice, as discussed in more depth in the reactive
oxygen species section of this introduction.
The presence of hypercapnia under CH conditions attenuates pulmonary vascular
remodeling (Ooi et al., 2000).

Kantores et al. showed that 10% CO2 exposure,

concomitant with normobaric hypoxia, attenuated right ventricular hypertrophy and the
associated medial wall thickening and number of muscularized small pulmonary arteries
(Kantores et al., 2006). This finding is consistent with studies from our laboratory
comparing hypocapnic and eucapnic IH, in which we found that the presence of
supplemental CO2 blunts the muscularization of small pulmonary arteries (Snow et al.,
2008). The mechanism by which CO2 opposes pulmonary vascular remodeling is unclear
but may be related to an inhibitory effect of CO2 on ET-1 expression (Kantores et al.,
2006). Whole lung ET-1 as well as pulmonary arterial prepro-ET-1 protein levels are
elevated in CH rats, but this is blunted by the presence of supplemental CO2. In addition,
ETA/B receptor inhibition prevents the CH-induced pulmonary arterial wall thickening
(Kantores et al., 2006). These results indicate that CO2 inhibits CH-induced pulmonary
vascular remodeling via down regulation of ET-1 signaling in the lung. A similar effect
of CO2 may exist in the setting of IH.

We therefore compared effects of CO2

supplementation on pulmonary vasoconstrictor reactivity and indices of pulmonary
hypertension.
Hypoxic pulmonary vasoconstriction. Hypoxic pulmonary vasoconstriction
(HPV) is a compensatory response to low alveolar O2 tension. In physiological or
pathophysiological situations in which a fraction of alveoli are hypoxic, often due to
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airway constriction or obstruction, HPV facilitates the diversion of blood from these
poorly ventilated regions toward those with better ventilation.
HPV can be divided into two phases.

The first phase appears to be Ca2+

dependent because Ca2+ channel inhibitors prevent this response. Phase I is also at least
partially intrinsic to the VSM, given that phase I persists following disruption of the
endothelium (Leach et al., 1994).

Isolated PASMCs contract in response to acute

hypoxia (Madden et al., 1992), suggesting that at least the initiation of HPV is intrinsic to
the SMC. The more slowly developing phase II, however, appears to be completely
endothelium-dependent and mediated by VSM Ca2+ sensitization (Robertson et al.,
2003). The endothelium-derived vasoconstrictor ET-1 may act as a priming stimulus for
HPV (Liu et al., 2001;Sato et al., 2000), which could partially explain the contribution of
the endothelium to these responses.

In addition, PKC activation potentiates HPV

responses in isolated lungs, suggesting that PKC contributes to hypoxia-induced
constriction (Orton et al., 1990).
A crucial step in the mechanism of HPV is O2 sensing. Two opposing models for
intrinsic VSM O2 sensing have gained support over the years. Both theories support an
important role for mitochondrial reactive oxygen species (ROS), however the conflict lies
in whether ROS increase or decrease with hypoxia. Based on measurements of ROS in
isolated, perfused lungs as well as in endothelium-denuded small pulmonary arteries
exposed to hypoxia, it is suggested that the mitochondria of PASMCs produce a tonic
level of ROS, which is inhibited by lower O2 tension (Archer et al., 1989;Michelakis et
al., 2002). The decrease in ROS is proposed to cause a more reduced cytosol which then
inhibits K+ channels, effectively depolarizing the SMC membrane potential and
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activating L-type Ca2+ channels to mediate Ca2+ influx and VSM cell contraction (Weir &
Archer, 1995). Conversely, a hypoxic increase in ROS in the mitochondria of PASMC
(Rathore et al., 2008) is suggested to trigger Ca2+ release from the sarcoplasmic reticulum
(SR) which in turn activates store-operated Ca2+ entry (SOCE) (Robertson et al.,
2000;Waypa et al., 2001), contributing to a rise in VSM [Ca2+]i and cell contraction.
Further studies are necessary to reconcile these opposing theories.
CH-induced PH is associated with a blunted HPV response. It was initially
reported that 4-6 weeks of hypobaric hypoxia attenuates pressor responses to acute
hypoxia (McMurtry et al., 1978) in lungs isolated from rats. It was subsequently found
that merely 40 hours of hypobaric hypoxia were sufficient to diminish pressor responses
to acute hypoxia (McMurtry et al., 1980;Reeve et al., 2001) A similar phenomenon
occurs in rabbits exposed to normobaric hypoxia (Weissmann et al., 2003).

This

decreased responsiveness to hypoxia appears to be related to decreased K+ channel
expression and activity and may be related to changes in SMC redox status (Reeve et al.,
2001) and NO production (Weissmann et al., 2003). These data suggest that HPV is not
the mechanism which sustains PH in the setting of CH.
Although little is known about effects of IH on HPV, repeated exposure to IH in a
canine lobar hypoxic model suggests that repeated exposure to acute hypoxia augments
HPV responses (Benumof, 1983). This idea is consistent with the effect of IH on the
carotid body. IH augments carotid body and sympathetic effector responses to acute
hypoxia in addition to facilitating persistent activation of carotid body and sympathetic
output (Peng et al., 2003). In agreement with these findings from studies of IH-exposed
animals, SA patients experience persistent sympathetic nervous system activity (Carlson
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et al., 1993). However, unpublished results from our laboratory suggest that, similar to
CH, IH attenuates HPV responses in isolated lungs. These discrepant findings
demonstrate the need for further investigation into the effect of IH on acute hypoxic
vasoreactivity.
Agonist-Induced Vasoconstriction. VSM cell contractile state is also influenced
by hormones, neurotransmitters and other paracrine agonists, which bind to specific
receptors on the cell membrane. Many of these factors such as ET-1, UTP and 5-HT bind
to Gq-coupled receptors. Upon ligand binding, these receptors activate phospholipase C
which cleaves phosphatidyl inositol bisphosphate (PIP2) yielding diacylglycerol (DAG)
and inositol trisphosphate (IP3). IP3 binds to and activates IP3 receptors on the SR,
causing Ca2+ release and an increase in [Ca2+]i. This Ca2+ release mediates SOCE, further
increasing [Ca2+]i. In addition, DAG directly activates receptor-operated cation channels
(ROC) and also increases PKC activity, serving as an indirect activator of ROC. Thus,
ROCs provide an additional contribution to the agonist-mediated increase in [Ca2+]i.
Active pulmonary vasoconstriction contributes to PH, as demonstrated by the
decrease in PAP in response to acute vasodilator inhalation in PH patients (MacNee et
al., 1983;Moinard et al., 1994) and rats (Oka et al., 1993). It has been appreciated for
some time that agonist-induced pulmonary vasoconstriction is augmented in experimental
models of PH (McMurtry et al., 1978). McMurtry et al. showed that isolated lungs from
CH rats were hyperresponsive to agonists such as angiotensin and prostaglandin F2α
(McMurtry et al., 1978). Augmented pulmonary vasoconstrictor reactivity in PH has
been confirmed by studies showing increased vasoreactivity to U-46619, ET-1, 5-HT,
and norepinephrine (Porcelli & Bergman, 1983;Raffestin et al., 1991;Snow et al.,
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2008;Wanstall & O'Donnell, 1990). ET receptor inhibition prevents hypoxic PH (Oparil
et al., 1995) and reverses established PH (DiCarlo et al., 1995). ETA and ETB receptor
expression is increased during hypoxia (Li et al., 1994) and ET-1 mRNA, protein and
plasma levels are increased by CH (Li et al., 1994), suggesting that ET-1-induced
vasoconstriction may contribute to CH-induced PH.
Similar to the setting of CH, agonist-induced vasoconstriction may contribute to
IH-induced PH. Indeed, previous studies from our laboratory and others indicate that IH
increases pulmonary vasoconstrictor reactivity to agonists, such as the thromboxane
mimetic U-46619 (Snow et al., 2008), 5-HT and ET-1 (Thomas & Wanstall, 2003).
Thus, increases in agonist-induced pulmonary vasoconstriction may provide an important
contribution to IH-induced PH, however the mechanism by which this occurs is not
understood and is a focus of this dissertation.

Mechanisms of VSM Cell Contraction
The contractile state of VSM cells is largely regulated by changes in [Ca2+]i. Four
Ca2+ ions bind to calmodulin, which can then activate myosin light chain kinase
(MLCK). When activated, MLCK phosphorylates the myosin regulatory light chain
(MLC), facilitating actin-myosin interaction and cell shortening (Figure 2) (Takashima,
2009). Mechanisms of increases in VSM [Ca2+]i are discussed below.
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Figure 2. Vascular smooth muscle cell contraction is regulated by both increases in
[Ca2+]i as well as increases in Ca2+ sensitivity in response to receptor-mediated
agonists. Rho kinase (ROK), myosin light chain (MLC), myosin light chain
phosphatase (MLCP), myosin light chain kinase (MLCK).
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VSM Ca2+ Entry Pathways
Voltage-Gated Ca2+ Entry. Voltage-gated Ca2+ channels become permeable to
Ca2+ upon membrane depolarization. The L-type Ca2+ channel has been extensively
characterized in VSM. These channels play a crucial role in coupling electrical signals to
chemical signals. For example, ET-1 elicits depolarization of the PASMC membrane by
inhibiting voltage-gated potassium channels (Kv) (Shimoda et al., 2001), which are
thought to be the main regulators of resting membrane potential in these cells (Shimoda
et al., 1998). Therefore, ET-1-induced depolarization activates L-type Ca2+ channels to
mediate Ca2+ influx and increased VSM cell tone.

L-type Ca2+ channels are also

important in mediating HPV, as described above.
Store-operated Ca2+ entry. Store-operated Ca2+ entry (SOCE) is a ubiquitous
Ca2+ entry mechanism which is activated by a fall in endoplasmic reticulum (ER) or
sarcoplasmic reticulum (SR) [Ca2+]i. Originally termed capacitative Ca2+ entry (Putney,
Jr., 1986), SOCE occurs in response to receptor-mediated agonists which generate IP3
from PIP2. IP3 then binds to the IP3 receptor (IP3R) on the SR, eliciting Ca2+ release. In
addition to contributing to contraction in response to receptor-mediated agonists, SOCE
may facilitate refilling of the intracellular Ca2+ stores (Jousset et al., 2007;Parekh &
Putney, Jr., 2005). SOCE can be elicited by pharmacologically depleting SR Ca2+ stores
with sarcoplasmic endoplasmic reticulum Ca2+ ATPase (SERCA) pump inhibitors such
as thapsigargin and cyclopiazonic acid. The SR Ca2+ sensor appears to be stromal
interaction molecule 1 (STIM1) (Dziadek & Johnstone, 2007;Lu et al., 2009). Until
recently, the best candidates for SOC proteins were the canonical transient receptor
potential (TRPC) family of non-selective ion channels, which assemble as homo- and
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hetero-tetramers to form a functional channel (Sweeney et al., 2002b). Studies using
siRNA against TRPC1 show that it is an essential component of SOCE (Sweeney et al.,
2002b). However, more recently, evidence suggests an important role for TRPC5 (Ma et
al., 2008) and Orai1 in mediating SOCE (Potier et al., 2009). Jernigan et al. have
recently shown that acid-sensing ion channels (ASIC) additionally conduct Ca2+ in
response to store depletion in pulmonary arteries (Jernigan et al., 2009). It is likely that
multiple influx pathways act in concert to mediate functional SOCE.
Receptor-operated Ca2+ entry.

Another important Ca2+ entry pathway that

contributes to agonist-induced increases in [Ca2+]i is receptor–operated Ca2+ entry
(ROCE). As discussed above, when an agonist binds a Gq-coupled receptor, PLC cleaves
PIP2 into IP3 and diacylglycerol (DAG). While IP3 has effects on IP3-sensitive Ca2+
stores, DAG activates receptor-operated non-selective cation channels (ROC) to mediate
Ca2+ influx. Similar to SOC, TRPC proteins assemble as homo- and hetero-tetramers to
form ROC. The DAG analog, OAG (1-Oleoyl-2-acetyl-sn-glycerol), activates ROC,
which in general are comprised of TRPC 3/6/7 proteins (Hofmann et al., 2000). In
PASMCs, TRPC6 is thought to mediate ROCE (Lin et al., 2004). The mechanism by
which DAG activates ROC may be both direct (Trebak et al., 2003) and indirect via
activation of PKC and subsequent phosphorylation of TRPC proteins (Venkatachalam et
al., 2003).
The above mechanisms of increasing VSM cell [Ca2+]i facilitate an increase in
MLCK activity and cell contraction. In addition to mediating VSM cell contraction via
changes in [Ca2+]i, agonists can increase contraction via changes in sensitivity to Ca2+.
DAG generation in response to agonist stimulation activates PKC which is a well
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characterized regulator of Ca2+ sensitivity. A second mechanism of Ca2+ sensitization is
involves stimulation of Rho kinase (ROK). Regulation of VSM tone via alterations in
Ca2+ sensitivity is discussed below.

Ca2+ Sensitization Mechanisms
Classically, VSM cell contraction was thought to be regulated mainly by [Ca2+]i
levels, which are largely controlled by the mechanisms discussed above. More recently,
however, it has been found that the sensitivity of the VSM to [Ca2+]i is a major regulator
of the contractility of the cell. As depicted in figure 2, this is accomplished by regulation
of myosin light chain phosphatase (MLCP), which when active dephosphorylates the
MLC, thus decreasing actin-myosin cross-bridge cycling. Two of the main signaling
molecules which regulate MLCP activity are Rho kinase (ROK) and PKC. Both ROK
and PKC mediate a decrease in MLCP activity, resulting in contraction that is largely
independent of changes in [Ca2+]i. This phenomenon is termed Ca2+ sensitization. In
addition to regulation of MLCP activity, VSM cell contraction can be regulated at the
level of actin, whereby actin polymerization leads to an increase in VSM cell tone.
Specifically, pressure-induced tone appears to be mediated in part by increases in
filamentous actin, with inhibitors of actin polymerization attenuating myogenic
constriction (Cipolla et al., 2002;Flavahan et al., 2005).
Rho Kinase. The serine/threonine kinase ROK is activated by the small GTPase
RhoA in response to stimulation with pulmonary vasoconstrictors such as ET-1,
phenylephrine and 5-HT (Figure 2) (Damron et al., 2002;Guilluy et al., 2009;Jernigan et
al., 2008). Binding of RhoA to the Rho binding domain of ROK causes a conformational
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change and autophosphorylation/activation of the kinase (Somlyo & Somlyo, 2003).
When activated, ROK phosphorylates MLCP at two main sites, T696 and T853 (Kawano
et al., 2002). Phosphorylation at T696 inhibits MLCP activity, whereas phosphorylation
at T853 interferes with the binding of the MYPT1 subunit to myosin, decreasing
phosphatase activity of MLCP (Feng et al., 1999).

In addition, ROK can mediate

agonist-induced actin polymerization, which provides an additional contribution to VSM
contraction (Maekawa et al., 1999).
PKC. In addition to ROK-dependent Ca2+ sensitization, PKC mediates the other
classical Ca2+ sensitization pathway by its phosphorylation of CPI-17 (Figure 2) (Khalil
et al., 1992a). PKC is a key regulatory enzyme in the pulmonary circulation, contributing
to both VSM cell contractility and proliferation (Barman, 2007;Bobik et al., 1990). PKC
is a serine/threonine kinase which consists of at least 12 isoforms in three classes. To be
active, all PKC isoforms require phosphorylation by phosphoinositide dependent kinase
and at least one autophosphorylation. The autophosphorylation is facilitated by the
conformational change incurred by membrane binding. The main difference between the
isoforms of the three classes lies in the mechanism by which they are targeted to the
membrane.

Classical PKC isoforms (i.e. α/β) are regulated by both Ca2+ and

diacylglycerol (DAG), whereas the novel PKC isoforms (i.e. δ) require DAG binding, but
are regulated independently of changes in Ca2+ (Table 1). The atypical PKC isoforms are
activated by neither increases in [Ca2+]i nor DAG, but rather depend on phosphatidyl
serine binding and phosphorylation (Table 1) (Violin & Newton, 2003). Several of these
isoforms are expressed in VSM, with the expression profile being dependent on species,
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Table 1: PKC Classes and Activation Mechanisms
PKC Class

Isoforms

Activated by

Classical

α, βI, βII, γ

Ca2+ and DAG

Novel

δ, ε, η, θ, μ

DAG

Atypical

ζ, ι, λ

Phosphatidyl serine binding
and phosphorylation
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as well as the type and order of vessel being studied (Haller et al., 1995;Khalil et al.,
1992b).
PKC mediates inhibition of MLCP via phosphorylation of the 17 kDa peptide
CPI-17. Phosphorylation at the single site (Thr38) of CPI-17 is sufficient to inhibit
MLCP, resulting in greater Ca2+ sensitivity of MLC and SMC contraction (Kitazawa et
al., 1999). Although the MYPT1 subunit of MLCP is highly regulated by ROK and other
enzymes, CPI-17 exerts its effects on smooth muscle Ca2+ sensitivity by inhibiting the
catalytic subunit of MLCP, PP1.

VSM Ca2+ Homeostasis and Myofilament Ca2+ Sensitivity in Pulmonary
Hypertension
Basal Ca2+.

Basal VSM cell [Ca2+]i is elevated in PH (Golovina et al.,

2001;Yuan et al., 1998). Ca2+ influx through L-type VGCC represents a major Ca2+
influx pathway in PASMC.

Given that L channels are activated by membrane

depolarization and PASMC Em is more depolarized following CH (Naik et al., 2005), it is
possible that Ca2+ influx through L channels contributes to elevated basal Ca2+ observed
following CH. In agreement with this possibility, removal of extracellular Ca2+ decreases
basal Ca2+ in PASMC from CH animals but not controls (Shimoda et al., 2000). Mn2+
quenching of fura-2 fluorescence is more rapid in PASMC from CH animals, further
supporting an elevation in Ca2+ influx (Lin et al., 2007). However, Shimoda et al. found
that inhibition of L channels under basal conditions does not affect basal VSM Ca2+ in
either control or CH cells (Shimoda et al., 2000). Other sources of Ca2+ influx, such as
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basal SOC and ROC activity could also mediate increased basal VSM [Ca2+]i. Changes in
SOCE and ROCE in PH are discussed below.
Despite frequent reports of elevated basal pulmonary VSM [Ca2+]i in PH, our
laboratory has not observed differences in resting Ca2+ between PASMC from control
and CH Sprague Dawley rats (Broughton et al., 2008;Jernigan et al., 2006;Snow et al.,
2009). However, this appears to be dependent on the strain of rat used, because Wistar
rats do demonstrate an increase in basal PASMC [Ca2+]i following exposure to CH (Snow
et al., 2009). Elevations in basal VSM [Ca2+]i could contribute to the development of PH
through increased vasoconstriction, expression of pro-growth genes and vascular
remodeling.

SOCE and ROCE. Discrepant results exist regarding effects of CH on these Ca2+
entry pathways in pulmonary VSM. Lin and colleagues reported that CH increases
pulmonary VSM SOCE and ROCE in Wistar rats which may contribute to elevated basal
Ca2+ and spontaneous tone as well as vasoconstrictor reactivity in PH (Lin et al., 2004).
However, previous studies from our laboratory have revealed a decrease in SOCE and
ROCE following CH in Sprague Dawley rats (Jernigan et al., 2006). Based on more
recent studies from our laboratory, differential effects of CH on pulmonary VSM SOCE
and ROCE appear to be dependent on strain, with Wistar rats representing a response
which is more similar to that found in pulmonary hypertensive mice and humans
(Golovina et al., 2001;Snow et al., 2009;Wang et al., 2006a;Yuan et al., 1998;Zhang et
al., 2007).

24

In PASMC from pulmonary hypertensive animals, ROCE has been shown to be
both greater (Lin et al., 2004;Wang et al., 2006a) and less (Jernigan et al., 2006;Snow et
al., 2009) than control tissues. Comparison of the effects of CH on ROCE in pulmonary
arteries from Sprague Dawley and Wistar rats revealed no difference in ET-1-induced
ROCE (Snow et al., 2009).

Therefore, the contrasting results concerning ROCE in

pulmonary VSM from pulmonary hypertensive patients and animals are likely a function
of either tissue preparation (i.e. proximal vs. distal arteries) or protocol (i.e. DAG vs. ET1-stimulated ROCE).

Myofilament Ca2+ Sensitivity.

Ca2+ sensitization of the VSM contractile

apparatus represents a significant contribution to the enhanced pulmonary vascular
resistance in PH (Nagaoka et al., 2004). In particular, many lines of evidence support a
role for ROK-mediated pulmonary vasoconstriction in CH-induced PH (Oka et al., 2008).
First, acute administration of ROK inhibitors elicits vasodilation in CH hypertensive rat
lungs and nearly normalizes pressures between CH and control rats (Nagaoka et al.,
2004). It was subsequently confirmed by Hyvelin et al. (Hyvelin et al., 2005)) and
McNamara et al. (McNamara et al., 2008) that ROK-mediated vasoconstriction was
responsible for mediating CH-induced increases in PAP in CH-exposed adult and
neonatal rats. In addition, acute administration of an inhaled ROK inhibitor decreased
PAP in rats with monocrotaline-induced PH and the spontaneously pulmonary
hypertensive fawn-hooded rats (Nagaoka et al., 2005). These studies suggest that ROK
contributes to the development of PH via active vasoconstriction and not merely via
vascular remodeling.
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CH increases both RhoA activity and ROK expression in pulmonary arteries to
mediate elevated ROK-dependent vasoconstriction in pulmonary arteries (Hyvelin et al.,
2005;Jernigan et al., 2004b).

Furthermore, effects of NO to dilate the pulmonary

vasculature are mediated through inhibition ROK-dependent Ca2+ sensitization (Jernigan
et al., 2004b). Agonist-mediated constriction (Jernigan et al., 2008;Weigand et al., 2006)
and spontaneous, myogenic tone (Broughton et al., 2008) are largely dependent on ROKdependent Ca2+ sensitization following CH.

In addition, CH-induced PH can be

prevented by chronic ROK inhibition (Hyvelin et al., 2005;McMurtry et al., 2003).
These studies underscore the importance of ROK-dependent mechanisms in the
development of PH.
Although most evidence suggests ROK is the main mediator of Ca2+ sensitization
in hypertensive pulmonary arteries, one study points to a role for PKC-dependent Ca2+
sensitization, specifically in the fawn hooded rat model of idiopathic PH (Barman, 2007).
ET-1-mediated constriction is elevated in the pulmonary VSM of these rats and inhibition
of classical PKC isoforms potently inhibits this constriction (Barman, 2007). However, it
is unclear if this is due to a relatively higher PKC expression or activity in fawn-hooded
rats compared to controls. PKC-dependent constriction of systemic arteries is enhanced
following IH (Allahdadi et al., 2008b). The role of PKC in the pulmonary circulation
following IH is unclear, but it is possible that similar to its role in the systemic
circulation, PKC mediates constriction in the pulmonary circulation following IH and
contributes to IH-induced PH. A focus of this study is, therefore, to determine the
contribution of PKC-dependent Ca2+ sensitization to IH-induced increases in pulmonary
vasoconstrictor reactivity.
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Role of Reactive Oxygen Species (ROS) in Vascular Signaling and Pathology
Virtually all types of vascular cells produce superoxide anion (O2-) and hydrogen
peroxide (H2O2) (Dikalov et al., 2008;Matsubara & Ziff, 1986;Suzuki & Ford, 1999). O2is generated when an electron is donated to molecular oxygen (O2) and this is catalyzed
by oxidases, such as NADPH oxidases (NOX) and xanthine oxidase (XO). O2- itself may
modulate vascular signaling cascades, regulating contractility, cell migration and
proliferation, in addition to providing a source for other ROS. Dismutation of O2- by
superoxide dismutase (SOD) produces H2O2 which is a more stable form of ROS and has
been shown to have direct signaling properties. While there is basal production of O2-,
constitutive activity of SOD maintains these levels low. The main enzymes which
eliminate cellular H2O2 are catalase, glutathione peroxidase and peroxiredoxins which
convert H2O2 into H2O and other metabolites (Rhee et al., 1999).

Under normal

physiological conditions, antioxidant enzymes are sufficient to keep ROS low (Wolin,
2009).

Under pathological conditions, elevated levels of ROS due to enhanced

production or decreased metabolism can lead to cellular oxidative stress.
One of the best understood effects of O2- on vascular contractility arises from its
affinity for nitric oxide (NO) which it readily scavenges and inactivates to form
peroxynitrite (ONOO-) (Rubanyi & Vanhoutte, 1986). Diminished NO bioavailability
impairs endothelium-dependent relaxation in vessels with an intact endothelium. In
addition, oxidative stress in the endothelium causes oxidation of BH4, an essential
cofactor for endothelial nitric oxide synthase (eNOS), resulting in decreased production
of NO and increased production of O2-, a process often referred to as eNOS uncoupling
(Li et al., 2006). The direct effects of O2- on VSM cell contractility remain less well
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understood, but recent evidence suggests that O2- constricts intrapulmonary arteries via
ROK-dependent Ca2+ sensitization (Jernigan et al., 2008;Knock et al., 2008). H2O2 on the
other hand has been characterized as both a vasoconstrictor and a vasodilator, based upon
the vascular bed and the signaling cascade in question (Ardanaz et al., 2008;Burke &
Wolin, 1987;Lin et al., 2007). In PASMCs, exogenous H2O2 causes an increase in [Ca2+]i
via both SR Ca2+ release and Ca2+ influx to mediate cell contraction (Lin et al., 2007).
ROS appear to contribute to the development of PH (DeMarco et al.,
2008;Elmedal et al., 2004) through vascular remodeling (Jankov et al., 2008) and
potentially vasoconstriction. Hypoxia has been shown to elicit an increase in pulmonary
artery ROS levels (Killilea et al., 2000;Wang et al., 2006b;Waypa et al., 2001), and O2generation in the vasculature is an effective stimulus for both vasoconstriction and
vascular remodeling (Nagaoka et al., 2004). Superoxide-dependent RhoA activation
contributes to enhanced pulmonary artery vasoconstrictor reactivity following CH
(Jernigan et al., 2008). As discussed blow, a major source of ROS in the setting of CH is
NADPH oxidase (NOX) which contributes to the development of CH-induced PH. Wild
type mice exposed to normobaric hypoxia have increased pulmonary artery O2generation, pulmonary vascular remodeling and right ventricular hypertrophy, whereas
these alterations are prevented in mice lacking the gp91phox subunit of NOX (Liu et al.,
2006). CH increases expression of NOX4 in pulmonary arteries (Mittal et al., 2007).
Similarly, NOX-derived O2- contributes to pulmonary vascular remodeling following IH
(Nisbet et al., 2008).

Effects of ROS on vasoconstriction in the setting of IH are

unknown and are a focus of the present study.
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Enzymatic Sources of ROS
NADPH Oxidase. NOX was first characterized as a key mediator of bactericidal
activity of phagocytes through its production of large quantities of O2- during the
oxidative burst. NOX isoforms comprise a multisubunit class of enzymes which function
in plasma membranes of endothelial cells, VSM cells and fibroblasts in the vascular wall
(Forstermann, 2008). Two membrane spanning subunits, NOX1 (or NOX2 also known
as gp91phox) and p22phox, three cytosolic subunits, p47phox, p67phox and p40phox and a
regulatory small G protein Rac assemble when activated to catalyze the production of O2from molecular O2 (Cave, 2009) (Figure 3). In addition, NOX4 and NOX5 are expressed
in some vascular cells, where they may function independent of cytosolic subunits.
NOX is a major source of O2- in vascular endothelium and SMCs (Mohazzab et
al., 1994;Pagano et al., 1993). Vascular forms of NOX (i.e. NOX1,2,4,5)are low-output
enzymes, estimated to produce one third the amount of O2- produced by neutrophil NOX
(Griendling & Ushio-Fukai, 1998). Several animal models of systemic hypertension
have been shown to be dependent upon NOX (Li et al., 2006;Matsuno et al., 2005). In
addition, NOX is implicated in contributing to PH. For example, NOX4 expression is
increased in pulmonary arteries from CH mice and human patients with idiopathic PH
(Mittal et al., 2007). Furthermore, Rac1 and p47phox expression are increased in lungs
from pulmonary hypertensive lambs, and treatment with NOX inhibitors decreases ROS
levels in these lungs, suggesting that NOX-dependent ROS to contribute to the
development of PH (Grobe et al., 2006).
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Figure 3. NADPH oxidase (NOX2-prototype NOX) is activated when three
cytosolic subunits and a regulatory G protein (rac) assemble with the membranespanning subunits (gp91phox and p22phox). The active enzyme uses NADPH as a
substrate and generates superoxide (O2-).
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CH increases O2- generation via NOX in intrapulmonary arteries, as shown by the
lack of an increase in ROS in CH-exposed mice lacking the gp91phox subunit (Liu et al.,
2006). Furthermore, knocking out the gp91phox subunit prevents CH-induced right
ventricular hypertrophy, pulmonary vascular remodeling as well as the increased
vasoconstrictor reactivity (Liu et al., 2006). Based on these findings that sustained
hypoxia elicits PH via NOX-dependent mechanisms, it is not surprising that NOX was
recently shown to contribute to IH-induced PH in mice (Nisbet et al., 2009). In this
study, Nisbet et al. found that exposure of mice to 8 weeks of IH induces PH, as
evidenced by an increase in RV wall thickness and RV systolic pressure in anesthetized
mice. This IH-induced PH is associated with decreased pulmonary arterial diameter,
(although the vasculature was not fully dilated prior to tissue fixation), increased NOX
subunit expression as well as O2- production in the lung (Nisbet et al., 2009).
Interestingly, the IH-induced PH and vascular remodeling did not occur in gp91phox
knockout mice. These results support a role for NOX-dependent pulmonary vascular
remodeling to mediate at least a component of IH-induced PH. However, the role of
NOX in pulmonary vasoconstriction following IH is unclear and is addressed in this
study.
Xanthine Oxidase. XO is another major source for vascular ROS under hypoxic
conditions. XO is an enzyme that catalyzes oxidative hydroxylation of purine substrates
and generates O2- (Borges et al., 2002). XO can be activated by hypoxia in cultured
PASMCs (Hassoun et al., 1994). In addition, Hoshikawa et al. found that normobaric
hypoxia increases lung XO activity and that treatment of adult rats with XO inhibitor
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allopurinol blunts CH-induced PH and associated pulmonary vascular remodeling
(Hoshikawa et al., 2001). Consistent with results in adult rats, XO inhibition in neonatal
rats blunts CH-induced PH and the associated pulmonary arterial remodeling (Jankov et
al., 2008). Based on these findings, we further evaluated the role of XO in augmented
vasoconstrictor reactivity following IH.
Mitochondrial Electron Transport Chain.

Mitochondria are considered the

primary cellular source of ROS formation under physiological conditions. When the
mitochondrial respiratory chain is uncoupled, ROS “leak” from complexes I and III.
Under normal conditions the mitochondria convert up to 5% of molecular oxygen to O2(Packer L., 2002), however these mitochondrial ROS are well buffered by antioxidants in
the mitochondria.

The mitochondrial Mn-SOD (SOD-2) is considered the major

antioxidant with regards to mitochondrial ROS generation (Faraci & Didion, 2004). This
is demonstrated by the finding that mice lacking functional Mn-SOD die within weeks of
birth due to cardiac abnormalities and mitochondrial damage (Packer L., 2002).
Under conditions of hypoxia/reoxygenation or IH, mitochondrial dysfunction
occurs and an increase in ROS production results (Grill et al., 1992). In obstructive SA
patients, changes in mitochondrial cytochrome oxidase redox state during obstructive
apneas contribute to elevated mitochondrial-derived ROS (McGown et al., 2003). The
occurrence of increased oxidative stress in systemic arteries, adrenal glands, liver and
carotid bodies of rats exposed to IH (Kumar et al., 2006;Kuri et al., 2007;Peng et al.,
2006;Troncoso Brindeiro et al., 2007) further supports the idea that IH increases ROS
formation.
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PASMC mitochondria are important in acutely sensing O2 levels, modulating
ROS production and mediating HPV responses, as discussed above (Archer et al., 2008).
Acute hypoxia may increase or decrease mitochondrial ROS generation to mediate
increases in PASMC Ca2+ and vasoconstriction (Waypa et al., 2006;Weir & Archer,
1995). Mitochondrial function in PASMC from patients with PH and fawn hooded rats
with PH was recently reported to be disrupted, resulting in decreased ROS generation
(Bonnet et al., 2006).

In contrast, Iqbal et al. reported that dysfunction of lung

mitochondrial complexes I and III mediates increased ROS production in pulmonary
hypertensive chickens (Iqbal et al., 2001).

The possibility that mitochondrial ROS

production could be similarly enhanced by IH and contribute to enhanced pulmonary
vasoconstrictor reactivity has not been studied. Therefore, an additional goal of the
present study is to evaluate the role of mitochondrial ROS in increased pulmonary
vasoconstrictor reactivity after IH.

Interactions Between ROS and Ca2+ Sensitization Pathways in Regulation of Vascular
Tone
ROS Activate Rho Kinase. ROS may mediate their effects on pulmonary
vasoconstriction via modulation of VSM Ca2+ sensitization pathways. In fact, O2- was
found to cause aortic ring contraction via ROK-dependent Ca2+ sensitization (Jin et al.,
2004). In addition, our laboratory has recently shown that CH increases pulmonary VSM
Ca2+ in response to vasoconstrictor agonists via ROS-dependent activation of RhoA/ROK
signaling (Jernigan et al., 2008). Consistent with these findings, Knock et. al. recently
showed that O2- generation with LY83583 constricts rat pulmonary arteries via ROK-
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dependent Ca2+ sensitization (Knock et al., 2008). Thus, it is plausible that IH increases
vasoconstrictor reactivity via ROS-dependent activation of ROK to mediate increased
pulmonary vascular resistance.
PKC Increases ROS Production.

PKC can stimulate ROS generation through

a variety of mechanisms, but the best characterized of those mechanisms is through
activation of NOX (Inoguchi et al., 2003;Rathore et al., 2008;Thamilselvan et al., 2009),
and PKC-dependent activation of NOX is a key component of many vascular signaling
pathways (Gupte et al., 2009). PKC phosphorylates and activates the p47phox subunit of
NOX (Park & Babior, 1997), which increases ROS generation. In bovine coronary
arteries, constriction in response to PKC activation is mediated largely by NOXdependent, XO-independent ROS generation. In rat femoral veins, inhibition of PKCε
attenuates H2O2 production in response to ischemia/reperfusion (Teng et al., 2008).
These studies demonstrate that PKC activation occurs proximal to ROS generation in
some vascular settings.
ROS Activate PKC.

Although PKC-dependent generation of ROS is well

established, recent studies show that ROS can also act proximal to PKC activation.
Hypoxia increases mitochondrial ROS generation in PASMCs, which in turn increases
PKCε activity (Rathore et al., 2006).

This results in an increase in VSM [Ca2+]i.

However, given the important role of PKC in Ca2+ sensitization, it is additionally possible
that ROS mediate pulmonary artery Ca2+ sensitization via PKC activation in the
hypertensive pulmonary circulation.
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Rationale and Specific Aims
SA is an increasingly common disorder in the United States, affecting an
estimated 1 in 5 adults (Young et al., 2002). Those who suffer from SA have frequent
nocturnal episodes of apnea, leading to nighttime IH which may be associated with
hypercapnia (Bady et al., 2000). In addition to causing systemic hypertension (Okabe et
al., 1995), SA can lead to right ventricular hypertrophy and PH (Guidry et al., 2001).
While some evidence suggests that IH increases pulmonary vasoconstrictor reactivity
(Snow et al., 2008;Thomas & Wanstall, 2003), the mechanism by which this occurs has
not been well studied. Vasoconstriction has been implicated as a major component of PH
in several animal models of the disease. However, it is not clear whether a similar
increase in pulmonary vasoreactivity occurs with IH and what the mechanism of this
potential increase is. Therefore, the objective of the current study was to determine the
effect of IH on pulmonary vasoconstrictor reactivity. We hypothesized that IH increases
agonist-induced vasoconstriction via mechanisms that involve ROK, PKC and ROS.
Furthermore, considering that continuous CO2 supplementation blunts the pulmonary
hypertensive response to CH (Kantores et al., 2006;Ooi et al., 2000), it is possible that
intermittent hypercapnia associated with SA provides a protective mechanism to limit the
severity of IH-induced PH.
To test our hypothesis, we exposed rats to IH (3 min cycles of 5% O2 air flush, 7
hr/day, 2 or 4 wk) with and without supplemental CO2, (5% CO2) or Sham conditions
(air/air cycling for equal duration). We characterized effects of CO2 supplementation on
blood gases during IH and found that IH causes hypocapnia in the absence of
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supplemental CO2 [hypocapnic IH (H-IH)] and maintains eucapnia in the presence of
CO2 [eucapnic IH (E-IH)]. We compared effects of E-IH and H-IH on indices of PH and
on vasoconstrictor reactivity in isolated small pulmonary arteries, and evaluated the
contribution of ROK, PKC and ROS to enhanced vasoreactivity following IH.

Specific Aims
1. Compare effects of E-IH and H-IH on indices of PH and vasoconstrictor
reactivity.
2. Assess the role of ROK in mediating right ventricular hypertrophy and
enhanced agonist-induced pulmonary vasoconstriction following E-IH
3. Assess

the

contribution

of

PKC

to

increased

agonist-mediated

vasoconstriction following E-IH.
4. Determine the contribution of ROS to the development of right ventricular
hypertrophy and enhanced agonist-induced vasoconstriction after E-IH.

Specific Aim 1:

Compare effects of E-IH and H-IH on indices of PH and

vasoconstrictor reactivity.
Hypotheses: 1) IH mediates PH and increases VSM sensitivity to receptor-mediated
vasoconstrictor agonists; 2)

supplemental CO2 attenuates IH-induced polycythemia,

arterial remodeling, right ventricular hypertrophy, and enhanced vasoconstrictor
sensitivity.
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Specific Aim 1.1 – Compare effects of E-IH and H-IH on arterial blood gases.
To characterize the degree to which breathing hypoxic/hypocapnic gas mixtures
leads to arterial blood gas alterations, we compared effects of IH with and without
supplemental CO2 on arterial O2 and CO2 tensions. Specifically, we measured arterial
PO2, PCO2 and pH in rats during H-IH and E-IH cycling. In addition, we assessed arterial
blood gases under noncycling conditions at the conclusion of the 4 week exposure period
to determine whether E-IH produces persistent alterations in blood gas tensions reflective
of renal compensation for respiratory acidosis/alkalosis.

Specific Aim 1.2 - Assess effects of E-IH and H-IH on right ventricular hypertrophy.
Right ventricular hypertrophy closely correlates with the degree of CH-induced
PH (Resta et al., 1999b). Therefore, we assessed right ventricular hypertrophy as an
index of the severity of IH-induced PH and further evaluated possible inhibitory effects of
supplemental CO2 on this hypertrophic response.

Specific Aim 1.3 – Assess the degree of polycythemia resulting from E-IH and H-IH
exposure.
It is well documented that CH elicits polycythemia and this factor often correlates
closely with the degree of developed PH. However, the effects of IH with and without
supplemental CO2 are less clear. We therefore measured hematocrit in both E-IH and HIH groups, as well as Sham-treated rats to determine the degree of polycythemia and to
evaluate potential inhibitory influences of supplemental CO2 on this response.
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Specific Aim 1.4 – Compare pulmonary arterial remodeling responses to E-IH and H-IH.
CH increases pulmonary arterial wall thickness and muscularization of arterioles,
a response that may contribute to elevated pulmonary vascular resistance and resultant
PH in this setting. To determine whether pulmonary arterial remodeling similarly occurs
in response to IH, and to assess effects of supplemental CO2 on this response, we
measured wall thickness of small pulmonary arteries from both E-IH and H-IH rats by
quantitative morphometric analyses of lung sections.

Specific Aim 1.5 - Assess effects of E-IH and H-IH on pulmonary vasoconstrictor
reactivity.
Increases in vasoconstrictor reactivity may provide an important contribution to
the development of CH-induced PH. CH augments vasoconstrictor reactivity of small
pulmonary arteries to a number of agonists including the thromboxane mimetic U-46619
(Eichinger & Walker, 1994;Resta & Walker, 1996), ET-1 (Jernigan et al., 2008), UTP
(Jernigan et al., 2004b) and 5-HT (Rodat et al., 2007). However, effects of IH on
pulmonary vasoreactivity have not been mechanistically investigated. We, therefore,
measured vasoconstrictor reactivity and VSM [Ca2+]i responses to ET-1, UTP and 5-HT
in isolated pulmonary arteries from Sham and IH rats.
A portion of the work in Aim 1 has been published (Snow et al., 2008).
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Specific Aim 2: Assess the role of ROK in mediating right ventricular hypertrophy
and enhanced agonist-induced pulmonary vasoconstriction following E-IH.
ROK represents a major agonist-dependent signaling pathway in VSM.

In

addition, CH increases ROK-dependent pulmonary VSM Ca2+ sensitization and ROK
contributes to CH-mediated PH.

However, whether a similar signaling mechanism

mediates augmented pulmonary vasoreactivity following E-IH has not been previously
addressed.
Hypothesis:

E-IH augments receptor-mediated pulmonary vasoconstriction through

ROK-dependent myofilament Ca2+ sensitization.

Specific Aim 2.1 - Evaluate the contribution of ROK to E-IH-induced RV hypertrophy.
To further strengthen this specific aim, we designed experiments to assess the role of
ROK in E-IH-dependent RV hypertrophy.

We inhibited ROK in vivo during E-IH

exposure and assessed RV hypertrophy as an index of PH.

Specific Aim 2.2 - Determine the role of ROK in mediating enhanced ET-1-induced
vasoconstrictor reactivity following E-IH.
Experiments in Specific Aim 1 revealed that E-IH augmented vasoconstrictor
reactivity to UTP, 5-HT and ET-1, suggesting that E-IH mediates a generalized increase
in reactivity to receptor-mediated agonists.

Therefore, we employed ET-1 as a

vasoconstrictor stimulus for all subsequent protocols to evaluate the mechanism of this
enhanced vasoreactivity following E-IH. In addition, preliminary studies for Specific
Aim 1 indicated that 4 weeks of E-IH exposure elicited RV hypertrophy in Wistar rats,
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indicative of PH. Because E-IH more closely approximates the blood gas changes seen
in patients with SA, all subsequent studies were performed in 4 week E-IH Wistar rats.
Therefore, we examined effects of pharmacologic ROK inhibition on vasoconstrictor and
VSM [Ca2+]i responses to ET-1 in isolated, endothelium disrupted pulmonary arteries
from Sham and E-IH rats.

Specific Aim 3: Assess the contribution of PKC to increased agonist-mediated
vasoconstriction following E-IH.
Based on findings in Specific Aim 2 that enhanced ET-1-induced constriction
after E-IH is mediated by Ca2+ sensitization but is independent of ROK, we sought an
alternative mechanism by which E-IH increases ET-1-induced vasoconstriction.

PKC

represents a major Ca2+ sensitization mechanism, and E-IH increases PKC-dependent
vasoconstriction to ET-1 in the systemic circulation (Allahdadi et al., 2008b). However,
effects of E-IH on PKC-dependent constriction in the pulmonary circulation are
unknown.
Hypothesis:

E-IH augments ET-1-induced vasoconstriction via PKC-dependent

signaling.

Specific Aim 3.1 - Determine the role of PKC in enhanced ET-1-induced
vasoconstriction following E-IH.
We used pharmacological approaches to examine the contribution of specific
PKC isoforms to ET-1-induced vasoconstriction in pulmonary arteries from Sham and EIH rats. These experiments employed a general PKC inhibitor (Ro 31-8220), a peptide
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inhibitor of the classical PKC isoforms (myr-PKC) and a novel PKC inhibitor (rottlerin)
to examine whether ET-1 mediates the elevated constriction following E-IH via a PKCdependent signaling mechanism.

Specific Aim 3.2 - Examine the effect of E-IH on pulmonary arterial PKC expression.
Given our preliminary finding that inhibition of PKCα/β isoforms attenuated ET1-induced constriction following E-IH, it was important to address whether E-IH
mediates enhanced vasoconstriction to ET-1 via an increase in PKCα or PKCβ
expression.

We therefore examined PKCα/βI/βII mRNA and protein expression in

isolated pulmonary arteries from Sham and E-IH rats using real time PCR and Western
blot analysis, respectively.

Specific Aim 4: Determine the contribution of ROS to the development of right
ventricular hypertrophy and enhanced agonist-induced vasoconstriction after E-IH.
Based on our findings in Specific Aim 3 that enhanced agonist-induced
vasoconstriction after E-IH is mediated by PKC, and given evidence that ROS can
activate PKC in pulmonary artery smooth muscle (Rathore et al., 2008), we proposed the
following hypothesis.
Hypothesis: E-IH augments agonist-induced pulmonary vasoconstriction via ROSdependent PKC activation.
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Specific Aim 4.1 – Determine the role of ROS in mediating E-IH-induced right
ventricular hypertrophy.
We sought to determine the in vivo role of ROS in E-IH-induced PH.

We

accomplished this by chronically administering the SOD mimetic, tempol, to Sham and
E-IH rats in their drinking water and assessing right ventricular hypertrophy at the end of
4 weeks.

Specific Aim 4.2- Assess the role of ROS in mediating augmented ET-1-induced
vasoconstrictor reactivity following E-IH.
Hypoxia has been shown to increase ROS such as O2- and H2O2 in PASMCs
(Killilea et al., 2000;Rathore et al., 2008;Waypa et al., 2001) and endothelial cells
(Grishko et al., 2001).

In addition, scavenging ROS attenuates the elevated ET-1-

induced pulmonary VSM Ca2+ sensitization following CH (Jernigan et al., 2008).
However, the effects of E-IH on ET-1-induced ROS generation and vasoconstriction are
unclear. We therefore conducted experiments to investigate effects of ROS scavenging
on vasoconstrictor and VSM [Ca2+]i responses to ET-1 in small pulmonary arteries from
Sham and E-IH rats.

Specific Aim 4.3 - Evaluate the relative contributions of NOX, XO, and mitochondrial
sources of ROS to increased ET-1-mediated vasoconstriction following E-IH
Major cellular sources of ROS include NOX, XO and mitochondria, and ROS
have been demonstrated to occupy many significant signaling roles in VSM cells.

We

designed experiments that examined whether ROS from each of these three sources
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contribute to the elevated ET-1-induced pulmonary vasoconstriction following E-IH.
These experiments employed inhibitors of NOX, XO and mitochondrial ROS generation
in isolated pulmonary arteries exposed to ET-1.

By inhibiting each of these ROS

generators, we sought to identify through which pathway ET-1 signals to mediate greater
constriction following E-IH.

Specific Aim 4.4 - Determine the effect of E-IH on pulmonary arterial ROS levels under
basal and stimulated conditions.
There is an increase in oxidant stress in the lungs (Kantores et al., 2006) of CH
pulmonary hypertensive rats as well as in patients with idiopathic PH. E-IH increases
vascular ROS levels, and this contributes to systemic hypertension (Troncoso Brindeiro
et al., 2007). We therefore examined whether E-IH increases pulmonary arterial ROS
levels using dihydroethidium (DHE) fluorescence measurements in isolated, pressurized
pulmonary arteries. Both basal and ET-1-stimulated O2- levels were measured in vessels
from Sham and E-IH rats.

Specific Aim 4.5 - Assess the role of ROS-dependent PKC activation in enhanced ET-1dependent vasoconstriction following E-IH.
Based on evidence that ROS can activate PKC in PASMC (Rathore et al., 2008), and
increased reactivity to ET-1 following E-IH involves both ROS and PKC, we sought to
determine whether ROS activate PKC to mediate vasoconstriction. We therefore
designed studies to investigate the relationship between ROS and PKC in mediating the
augmented ET-1-induced vasoconstriction following E-IH.
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CHAPTER II

METHODS

General Methods
All protocols used in this study were reviewed and approved by the Institutional
Animal Care and Use Committee of the University of New Mexico Health Sciences
Center.

Experimental Groups
Male Sprague Dawley and Wistar rats (Harlan Industries) were used for all
studies. H-IH, E-IH and Sham control rats were housed in Plexiglas chambers with free
access to food and water and exposed to either IH or air-air sham cycling for 7 hrs/day
for 2 or 4 wk as described previously (Allahdadi et al., 2005;Kanagy et al., 2001;Snow et
al., 2008). During exposure, the atmosphere was controlled by a constant flow of gas
through the boxes. For H-IH and E-IH treatment, the atmosphere alternated every 90 s
between room air and hypoxic (nadir FIO2 = 5%) or hypoxic/hypercapnic air (nadir FIO2 =
5%; peak FICO2 = 5%), respectively. Previous studies from our group have demonstrated
systemic hypertension characteristic of SA in this model of E-IH (Allahdadi et al.,
2005;Kanagy et al., 2001). For Sham exposure, the inflow gas was always room air but
the solenoid switches and inlets reproduced the noise and airflow disturbances of the IH
protocol. All animals were maintained on a 12:12hr light:dark cycle.
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Measurement of Right Ventricular Weight
Right ventricular hypertrophy was assessed as an index of PH, as previously
described (Resta et al., 1999a;Resta & Walker, 1996). Briefly, after isolation of the
heart, the atria and major vessels were removed from the ventricles. The right ventricle
(RV) was dissected from the left ventricle and septum (LV + S), and each was cleaned of
blood and weighed. The degree of right ventricular hypertrophy is expressed as the ratio
of RV to total ventricle weight (T) and as the ratio of RV to body weight (BW).

Isolation of Small Pulmonary Arteries for Dimensional Analysis
The isolated, pressurized pulmonary artery is a valuable tool for studying
vasoconstrictor reactivity, because it provides assessment of VSM function independent
of circulating factors, sympathetic innervation or shear stress.

In addition, the

endothelium can be disrupted to remove complicating influences such as endotheliumderived vasodilators or vasoconstrictors.

In addition, this approach allows for

simultaneous measurement of VSM [Ca2+]i. Due to the advantages of studying isolated,
pressurized pulmonary arteries, we employed this method in order to assess
vasoconstrictor reactivity, the role of Ca2+ signaling by measuring VSM [Ca2+]i and
vessel diameter.
Rats were anesthetized with pentobarbital sodium (200 mg/kg ip) and the heart
and lungs were exposed by midline thoracotomy.

The left lung was removed and

immediately placed in ice-cold physiological saline solution [(PSS) containing (in mM)
129.8 NaCl, 5.4 KCl, 0.5 NaH2PO4, 0.83 MgSO4, 10 NaHCO3, 1.8 CaCl2, and 5.5
glucose, all from Sigma]. A 4th-5th order intrapulmonary artery [~100-200 μm inner

45

diameter (ID), at 12 mmHg] of ~1 mm length and without side branches was dissected
free and transferred to a vessel chamber (Living Systems, CH-1) containing ice-cold PSS.
The proximal end of the artery was cannulated with a tapered glass pipette, secured in
place with a single strand of silk ligature, and gently flushed to remove any blood from
the lumen. Before cannulation of the distal end of the artery, a strand of moose mane was
passed through the lumen to disrupt the endothelium. The vessel was then stretched
longitudinally to approximate its in situ length and pressurized with a servo-controlled
peristaltic pump (Living Systems) to 12 mmHg. The absence of leaks was determined by
turning off the servo-control function and observing maintenance of pressure. Any
vessels with apparent leaks were discarded. The vessel chamber was transferred to the
stage of Nikon Eclipse TS100 microscope and the preparation superfused with PSS
equilibrated with a 10% O2, 6% CO2, and balance N2 gas mixture. A vessel chamber
cover was positioned to allow this same gas mixture to flow over the top of the chamber
bath. Bright-field images of vessels were obtained with an IonOptix CCD100M camera,
and dimensional analysis was performed by IonOptix Sarclen software to measure ID.
The effectiveness of endothelial disruption was verified by the lack of a vasodilatory
response to ACh (1 μM) in UTP (5 μM)-constricted vessels as we have previously
reported (Broughton et al., 2008;Jernigan et al., 2004b;Jernigan et al., 2004c;Jernigan et
al., 2006;Snow et al., 2009).

Measurement of VSM [Ca2+]i
Pressurized arteries (Figure 4) were loaded abluminally with the cell-permeant,
ratiometric, Ca2+-sensitive fluorescent indicator fura-2 AM (Molecular Probes) as
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described previously (Broughton et al., 2008;Jernigan et al., 2004b;Jernigan et al.,
2004c;Jernigan et al., 2006;Snow et al., 2009). Immediately before being loaded, fura-2
AM (1 mM in anhydrous DMSO) was mixed 2:1 with a 20% solution of pluronic acid
(Invitrogen) in DMSO, and this mixture was diluted in PSS to yield a final concentration
of 2 μM fura-2 AM and 0.05% pluronic acid. Arteries were incubated in this solution for
45 min at room temperature in the dark. The diluted fura-2 AM solution was equilibrated
with the 10% O2 gas mixture during this loading period. Vessels were then rinsed for 20
min with aerated PSS (37°C) to wash out excess dye and to allow for hydrolysis of AM
groups by intracellular esterases. Fura-2-loaded vessels were alternately excited at 340
and 380 nm with an IonOptix Hyperswitch dual excitation light source, and the respective
510 nm emissions were collected with a photomultiplier tube. Background-subtracted
340/380 emission ratios were calculated with IonOptix Ion Wizard software and recorded
continuously throughout the experiment, with simultaneous measurement of ID from red
wavelength bright-field images as described above.

In Situ Calibrations of VSM [Ca2+]i
In situ calibrations for Ca2+ were performed in pressurized arteries from Sham and
E-IH rats using methods similar to those previously described (Knot & Nelson, 1998);
Snow et al., 2008}. Following each experiment, as described above, the VSM was
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Figure 4. Isolated pressurized small pulmonary artery. Small pulmonary arteries
were dissected free from adjacent lung and airway tissue. Each end was
cannulated with a glass cannula and secured with strands of silk suture.
Intralumenal pressure was set at 12 mmHg by a pressure servo-controller.
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permeabilized to Ca2+ with 10 μM ionomycin, and the arteries were incubated with a bath
solution containing 140 mM KCl, 5 mM NaCl, 5 mM HEPES, 1 mM MgCl2 , 5 μM
nigericin and either 5 mM EGTA (low Ca2+ solution) or 2 mM CaCl2 (high Ca2+
solution), with a pH of 7.15 at 37°C until nadir and peak ratios were achieved.
Calibrations were performed in the presence of each drug used in the study.

Calculations and Statistical Analysis
Vasoconstrictor responses were calculated as a percent of baseline ID (following
pharmacological inhibitor administration) for all experiments. VSM [Ca2+]i is expressed
as the background-subtracted ratios of fluorescence (F) emitted following excitation at
340 and 380 nm (F340/F380).
All data are expressed as means ± SEM, and values of n refer to the number of
animals in each group. A t-test, one-way ANOVA or two-way ANOVA was used to
make comparisons when appropriate.

If differences were detected by ANOVA,

individual groups were compared with the Student-Newman-Keuls test. A probability of
P < 0.05 was accepted as significant for all comparisons.

Specific Aim 1:

Compare effects of E-IH and H-IH on indices of PH and

vasoconstrictor reactivity.
Preliminary studies indicated that IH alone elicits hypocapnic IH while IH with
CO2 supplementation causes eucapnic IH, thus we used the terminology H-IH and E-IH,
respectively to describe our models.
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Specific Aim 1.1 – Compare effects of E-IH and H-IH on arterial blood gases.
To characterize the degree of arterial hypoxemia induced by exposure to IH
cycling, in vivo arterial blood gases were measured just prior to, during and after
exposure to H-IH and E-IH. In addition, arterial PCO2 and pH were assessed in order to
determine whether exposure to supplemental CO2 leads to hypercapnia and arterial
acidosis or rather results in sustained eucapnic conditions. Blood samples were obtained
quickly during cycling via femoral arterial catheters. Blood was kept in capped syringes
on ice until being analyzed via ABL5 blood-gas analyzer.
To measure arterial blood gases, rats were anesthetized with isoflurane and
arterial lines surgically inserted in the abdominal aorta via the femoral artery. Catheters
were tunneled subcutaneously to the back of the neck where they were threaded through a
plastic harness into a metal spring. The line and spring exited the cage through a small
hole in the Plexiglas lid and were attached to a plastic swivel to allow the animal freedom
of movement within the cage. The line was filled with saline containing heparin (10
U/ml) and flushed daily. After 7 days of recovery, three arterial blood samples were
drawn to measure arterial blood gases using an ABL5 blood-gas analyzer: the first prior
to the H-IH or E-IH exposure, the second during the nadir or most hypoxic portion of the
cycling period (≈5%O2; ≈5%CO2) and the third at the peak of the air flush (≈20%O2;
≈0%CO2). These groups of rats were not carried out to 2 weeks of treatment for further
study.
To determine whether 4 weeks of E-IH exposure causes any long term arterial
blood gas derangements, an additional group of animals was instrumented with femoral
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arterial catheters at the end of 4 weeks E-IH exposure. Blood samples were then taken
before cycling began for the day, at the O2 nadir and at the peak of recovery, similar to
the above samples.

Specific Aim 1.2 - Assess effects of E-IH and H-IH on right ventricular hypertrophy.
To determine whether H-IH and E-IH elicit pulmonary hypertension, RV/T and
RV/BW were assessed as an index of pulmonary hypertension, as described above.
RV/T and RV/BW are measures of right ventricular hypertrophy which correlates with
increases in pulmonary artery pressure (Resta et al., 1999b).

Specific Aim 1.3 - Assess the degree of polycythemia resulting from E-IH and H-IH
exposure.
CH, which is a potent stimulus for the development of PH and right ventricular
hypertrophy, also elicits a profound increase in hematocrit. Hematocrit may be a
contributing factor to IH-induced PH, thus effects of IH on hematocrit were assessed.
Following lung isolation, blood samples were collected by direct cardiac puncture for
measurement of hematocrit. Exposure to supplemental CO2 has been shown to limit CHinduced polycythemia (Neckar et al., 2003), so the effects of both H-IH and E-IH on
hematocrit were assessed in rats exposed to 2 and 4 weeks of E-IH or Sham conditions.

Specific Aim 1.4 – Compare pulmonary arterial remodeling responses to E-IH and H-IH.
Idiopathic and CH-induced PH are associated with arterial remodeling which may
encroach on the pulmonary arterial lumen, increasing vascular resistance and manifesting
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a fixed component of pulmonary hypertension. To assess the degree of remodeling as a
further index of the degree of PH, vascular morphometry was performed on arterial cross
sections in lungs from each group of rats. Furthermore, CO2 supplementation blunts CHinduced pulmonary vascular remodeling (Kantores et al., 2006;Ooi et al., 2000).
Therefore, we assessed whether E-IH exposed rats had blunted pulmonary vascular
remodeling as compared with H-IH rats.
Vascular Morphometry
Effects of H-IH, and E-IH on pulmonary arterial remodeling were compared by
quantitative morphometric analyses of arterial cross-sections in lungs from each group of
rats as we have described previously (Resta et al., 1997;Resta et al., 1999b;Resta et al.,
2001). Lungs were isolated from rats using established procedures (Resta et al.,
1997;Resta et al., 1999a;Resta & Walker, 1996). Animals were anesthetized with sodium
pentobarbital (200 mg/kg, i.p.). After cannulating the trachea with a 17-gauge needle
stub, the lungs were ventilated using a Harvard positive pressure rodent ventilator (model
683) at a frequency of 55 breaths/min and a tidal volume of 2.5 mL with a warmed and
humidified gas mixture (6% CO2, 21% O2, balance N2). Peak inspiratory pressure was set
at 9 cm H2O and positive end-expiratory pressure was maintained at 3 cm H2O. After a
median sternotomy, heparin (100 U in 0.1 mL) was injected directly into the right
ventricle, and the pulmonary artery cannulated with a 13-gauge needle stub. The
preparation was immediately perfused at 0.8 mL/min by a Masterflex microprocessor
pump drive (model 7524-10) with PSS containing (in mM) 129.8 NaCl, 5.4 KCl, 0.5
NaH2PO4 0.83 MgSO4, 19 NaHCO3, 1.8 CaCl2 and 5.5 glucose with 4% bovine serum
albumin (wt/vol) added as a colloid. Papaverine (10-4 M) was also included in the PSS to
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maintain the vasculature in a dilated state during subsequent fixation. The left ventricle was
cannulated with a plastic tube (4 mm o.d.), and the heart and lungs were removed en bloc
and suspended in a humidified chamber maintained at 38°C. The perfusion rate was
gradually increased to 60 mL⋅min-1⋅kg body wt

-1

. Perfusate was pumped through a

water-jacketed bubble trap maintained at 38°C prior to entering the pulmonary
circulation. Experiments were performed with lungs in zone three conditions, achieved
by elevating the perfusate reservoir until venous pressure was ~12 mmHg. Previous work
from our laboratory suggests that maximal recruitment and thus maximal vascular surface
area is achieved at this flow and Pv (Eichinger & Walker, 1996). Pulmonary arterial
pressure and venous pressure were measured via side ports in the arterial and venous
lines using Spectramed model P23 XL pressure transducers and recorded on a Gould RS
3400 chart recorder. The vasculature was initially washed with 250 mL of PSS, followed
by 250 mL of fixative (0.1 M phosphate-buffered saline with 4% paraformaldehyde, 0.1%
glutaraldehyde, and 10-4 M papaverine). Lungs were additionally inflated with fixative via
the trachea to a pressure of 25 cm H2O during perfusion. The trachea was ligated with 2-0
silk, the arterial and venous lines simultaneously clamped, and the lungs immersed in
fixative. A transverse section (2-3 mm thick) of tissue from the left lobe was removed and
rinsed in phosphate-buffered saline. Sections were dehydrated in increasing concentrations
of ethanol, cleared in xylene, and mounted in paraffin.
Transverse sections of the left lung were cut (4 μm thick) and mounted onto
Superfrost Plus slides (Fisher Scientific).

Sections were stained for elastin (Sigma

Accustain Elastic Stain kit) and arteries identified by the presence of an internal elastic
lamina (Resta et al., 1997;Resta et al., 1999a;Resta et al., 2001). Vessels were examined
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with a ×40 objective on a Nikon Optiphot microscope, and images generated with a
digital CCD camera (Photometrics CoolSNAPcf) and processed with MetaMorph
software (Universal Imaging Corp.).

Measurements included medial circumference,

assessed from the outer margin of the external elastic lamina, and luminal diameter
(Greenberg & Kishiyama, 1993), and were made using a blinded analysis.
External and luminal arterial diameters were calculated from the medial and
luminal circumferences, respectively. Arterial wall thickness was assessed by subtracting
luminal radius from external radius, and expressed as a percent of external diameter
according to the following formula:
[(2 × wall thickness)/external diameter] × 100

Specific Aim 1.5 – Assess effects of E-IH and H-IH on vasoconstrictor reactivity.
Vasoconstriction may provide an important contribution to the development of
IH-induced PH. CH augments vasoconstrictor reactivity to agonists such as U-46619
(Eichinger & Walker, 1994;Resta & Walker, 1996), ET-1 (Jernigan et al., 2008), UTP
(Jernigan et al., 2004b) and 5-HT (Rodat et al., 2007). However, the effects of E-IH on
vasoconstrictor reactivity are unknown.

Based on findings in Specific Aim 1 that

polycythemia and pulmonary vascular remodeling are severely blunted in E-IH rats
compared to H-IH rats, in spite of considerable RV hypertrophy, we assessed
vasoconstrictor and VSM Ca2+ responses to receptor-mediated agonists.
Following the fura-2 AM loading and 20 min equilibration, vessels from either
group were exposed to increasing concentrations of ET-1 (10-11-10-7 M, Sigma), UTP (10-
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-3x10-3 M, Sigma), or 5-HT (10-9 - 3x10-3 M, Sigma) generating a concentration response

curve.

Specific Aim 2: Assess the role of ROK in mediating right ventrular hypertrophy
and enhanced agonist-induced pulmonary vasoconstriction following E-IH.
ROK mediates a major agonist-induced signaling pathway in VSM, and CH
increases ROK-dependent pulmonary VSM Ca2+ sensitization. Furthermore, ROK plays
a role in CH-induced PH. However, it is unclear if a similar signaling mechanism
contributes to augmented pulmonary vasoconstrictor reactivity following E-IH. Based on
findings in Specific Aim 1 that E-IH elicited RV hypertrophy and increased pulmonary
vasoconstrictor reactivity and because E-IH most closely approximates arterial blood gas
changes during SA, E-IH was used for all subsequent experiments.

Specific Aim 2.1 – Evaluate the contribution of ROK to E-IH-induced RV hypertrophy.
To examine the role of ROK in the development of E-IH-induced pulmonary
hypertension, in vivo ROK inhibition was performed with subsequent evaluation of right
ventricular hypertrophy as an index of PH.
Osmotic Pump Implantation
Rats were instrumented with subcutaneous osmotic minipumps to continuously
administer the ROK inhibitor fasudil for 4 weeks, during exposure to either Sham or EIH treatment.

Animals were placed in a clean Plexiglass chamber prefilled with

isoflurane gas (4.5%) for induction of anesthesia.
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Rats were then administered

buprenorphine (0.015 mg/kg s.c.) analgesia, atropine sulfate (54 μg, s.c.) to inhibit
bronchial secretions during surgery and 2-3 ml of warmed, sterile 0.9% NaCl solution
(s.c.) to minimize dehydration during surgery. The rats were then ventilated with 2%
isoflurane/98% oxygen, while secured to a surgical board. Osmotic pumps (Alzet model
2ML4) containing fasudil, dissolved in sterile saline, were implanted subcutaneously via
midline incision between the scapulae for 4 wk administration of fasudil (30 mg/kg/day,
LC Labs). This dose of fasudil has previously been shown to markedly reduce the
development of PH in fawn-hooded rats which spontaneously develop pulmonary
hypertension at moderate altitude (Nagaoka et al., 2006). Following overnight recovery
from surgery, rats were placed in either Sham or E-IH treatment.

Specific Aim 2.2 – Determine the role of ROK in mediating enhanced ET-1-induced
vasoconstrictor reactivity following E-IH.
To examine the possibility that a ROK-dependent myofilament Ca2+ sensitization
mechanism mediates the augmented vasoconstrictor reactivity following E-IH,
vasoconstrictor and VSM [Ca2+]i responses to ET-1 were assessed in pulmonary arteries
from Sham and E-IH rats in the presence of the ROK inhibitor fasudil (10 μM, LC Labs)
This concentration of fasudil inhibits ROK-dependent constriction in this preparation
(Broughton et al., 2008;Jernigan et al., 2008)

Specific Aim 3: Assess the contribution of PKC to increased agonist-mediated
vasoconstriction following E-IH.
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Specific Aim 3.1 - Determine the role of specific PKC isoforms in mediating enhanced
ET-1-induced vasoconstriction following E-IH.

ET-1-induced Vasoconstriction in Isolated Vessels in the Presence of a General PKC
Inhibitor
To determine if the augmented ET-1-induced VSM Ca2+ sensitization following
E-IH is mediated by PKC signaling, we measured vasoconstrictor and VSM Ca2+
responses to ET-1 in the presence of the general PKC inhibitor Ro 31-8220 in isolated
arteries from Sham and E-IH rats.

Prior to the application of increasing ET-1

concentrations, isolated, pressurized, fura-2 loaded vessels were exposed to Ro 31-8220
(5 μM, Biomol). This concentration of Ro 31-8220 has previously been reported to
inhibit contractile responses to 5-HT in isolated aortas from Wistar Kyoto and
spontaneously hypertensive rats (Budzyn et al., 2008). In addition, this concentration of
Ro 31-8220 abolished pulmonary vasoconstrictor responses to the phorbol ester phorbol
12-myristate 13-acetate PMA (10-8 - 3x10-6 M; Sigma) (See Results Figure 20). Ro 318220 acts by inhibiting the catalytic site of several PKC isoforms (Salamanca & Khalil,
2005). Following 10 minutes of equilibration with Ro 31-8220 and attainment of a stable
inner diameter and F340/F380 ratio, a concentration response curve to ET-1 was performed.

ET-1-Induced Constriction in Isolated Vessels in the Presence of a PKCα/β Inhibitor
To determine if the observed increase in ET-1-induced, PKC-dependent
vasoconstriction following E-IH is mediated by classical PKC isoforms, we measured
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ET-1-induced vasoconstriction in the presence of PKCα/β inhibition. Arteries were
pretreated with the cell permeable myristoylated PKCα/β pseudosubstrate inhibitor [2028] (myr-PKC) (10 μM, Biomol) and vasoconstriction to ET-1 was assessed as described
above. Incubation for 45 minutes with this concentration of myr-PKC partially inhibited
constrictions to PMA in pulmonary arteries (Results Figure 22) indicating that this
concentration of myr-PKC inhibits PKCα/β, although isoforms other than PKCα/β
contribute to PMA-induced constriction.

ET-1-induced Constriction in Isolated Vessels in the Presence of a PKCδ inhibitor
Given that ET-1-induced Ca2+ sensitization following E-IH is mediated by PKCδ
in systemic arteries (Allahdadi et al., 2008b), we sought to determine if the observed
increase in ET-1-induced pulmonary vasoconstriction following E-IH is mediated by the
novel PKC isoform (PKCδ). To address this question, pulmonary arterial vasoconstrictor
and VSM Ca2+ responses to ET-1 were assessed in the presence of the PKCδ inhibitor,
rottlerin (3 μM, Biomol).

Incubation with this concentration of rottlerin partially

inhibited constrictions to PMA in pulmonary arteries (Results Figure 24).

Specific Aim 3.2 - Examine the effect of E-IH on pulmonary arterial PKC expression.

Effects of E-IH on PKC mRNA expression
Given our finding that enhanced ET-1-mediated vasoconstriction following E-IH
is dependent on PKCα/β but not PKCδ, it is possible that there is an increase in
PKCα/β but not PKCδ mRNA expression. To determine the level of PKC α/β mRNA
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expression in pulmonary arteries from Sham and E-IH rats, we performed real time PCR
on mRNA isolated from pulmonary arteries from both groups.
Pulmonary arteries from Sham and E-IH rats were stored in RNAlater (Ambion).
Total RNA was isolated using the RNEasy Mini Kit (Qiagen) using the manufacturer’s
protocol. The High Capacity Reverse Transcription kit (Applied Biosystems) was used
for reverse transcription of total RNA to cDNA. For real-time PCR detection, Taqman
gene expression assay kits were used for rat PKCα and β.

Effects of E-IH on PKC Protein Expression
Expression of classical PKC isoforms was measured by western blot using
antibodies specific for PKCα, PKCβI and PKCβII, using a protocol similar to previously
published work (Jernigan et al., 2008).

To obtain sufficient tissue for analysis,

intrapulmonary arteries (approximately 2nd through 5th order) were isolated from the right
and left lungs of Sham and E-IH rats in HEPES-based PSS (in mM, 130 NaCl, 4 KCl, 1.2
MgSO4, 4 NaHCO3, 1.8 CaCl2, 10 HEPES, 1.18 KH2PO4, 6 glucose, and 0.03 EDTA, pH
adjusted to 7.4 with NaOH, all from Sigma). A HEPES-based PSS was used to maintain
a pH near 7.4 during incubation since the solution was not aerated with 10% O2, 6% CO2,
balance N2 gas mixture as in vasoreactivity studies. Each sample was homogenized in 10
mM Tris-HCl homogenization buffer containing 255 mM sucrose, 2 mM EDTA, 12 μM
leupeptin, 1 μM pepstatin A, 0.3 μM aprotinin, and 1 mM phenylmethylsulfonyl fluoride
(all from Sigma). Samples were centrifuged at 10,000 x g for 10 min at 4°C to remove
insoluble debris. The supernatant was collected, and sample protein concentrations were
determined by the Bradford method (Bio-Rad Protein Assay). Control experiments were
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performed with increasing concentrations of protein to ensure linearity of the
densitometry curve.
Pulmonary artery lysates (25 μg/lane) were separated by SDS-PAGE (7.5% TrisHCl gels, Bio-Rad) and transferred to polyvinylidene difluoride membranes. Blots were
blocked for 1 h at room temperature with 2.5% BSA and 2.5% milk in 0.05% Tween 20
(Bio-Rad) TBS. Blots were then incubated overnight at 4°C with monoclonal antibodies
to PKCα or PKCβI, or a polyclonal antibody raised against PKCβII (1:200, Santa Cruz).
For immunochemical labeling, blots were incubated 1 h at room temperature with goat
anti-mouse (PKCα/βI) or goat anti-rabbit (PKCβII) IgG-horseradish peroxidase (HRP,
1:3000, Bio-Rad). After chemiluminescence labeling (ECL, Amersham), PKCα/βI/βII
bands were detected by exposing the blots to chemiluminescence-sensitive film (Kodak).
Quantification of the bands was achieved by densitometric analysis of scanned images
(SigmaGel software, SPSS). Bands for PKCα/βI/βII were normalized to total protein
(Coomassie staining).

Calculations and Statistics
The normalized gene expression method (2-ΔΔCT) was used for relative
quantification of gene expression by real time PCR. For western blot, PKC band density
was compared to total protein density (Coomassie staining) for each lane. A probability
of P< 0.05 was accepted as statistically significant for all comparisons.
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Specific Aim 4: Determine the contribution of ROS to the development of right
ventricular hypertrophy and enhanced agonist-induced vasoconstriction after E-IH.

Specific Aim 4.1 - Assess the role of ROS in mediating E-IH-induced right ventricular
hypertrophy.
To assess whether elevated ROS levels following E-IH mediate the development
of PH, we treated Sham and E-IH rats with the superoxide dismutase mimetic tempol (4hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyl, Fluka) (1 mM in their drinking water) for
4 weeks. Right ventricular hypertrophy was then assessed as an index of pulmonary
hypertension.

This method for administering tempol has previously been shown to

attenuate E-IH-induced increases in systemic vascular ROS levels and to prevent the
development of systemic hypertension (Troncoso Brindeiro et al., 2007).

Specific Aim 4.2 - Assess the role of O2- and H2O2 in mediating augmented ET-1induced vasoconstrictor reactivity following E-IH.
The role of ROS in mediating augmented ET-1-induced vasoconstrictor reactivity
following E-IH was examined by scavenging ROS with the membrane permeable spin
trap agent, tiron (10 mM, Sigma), and performing concentration response curves to ET-1
as above. Tiron was present during the fura-2 loading period and throughout the rinse
period and remainder of the experiment. We have previously used this concentration of
tiron to scavenge ROS in isolated lungs (Jernigan et al., 2004a) and isolated arteries
(Jernigan et al., 2004c). In addition, we have shown that this concentration of tiron
attenuates xanthine/xanthine oxidase-induced increases in DCF fluorescence in isolated
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pulmonary arteries (Jernigan et al., 2004a). Vasoconstrictor reactivity was expressed as
percentage constriction from baseline (as above) and VSM Ca2+ responses were
expressed as a change in the F340/F380 ratio.
In addition, the role of H2O2 in mediating augmented vasoconstrictor reactivity to
ET-1 after E-IH was assessed by decreasing H2O2 levels with cell permeable PEGcatalase (250 U/ml, Sigma).

This concentration of PEG-catalase has been used to

scavenge H2O2 in isolated pulmonary arteries (Fike et al., 2008).

Specific Aim 4.3 - Evaluate the relative contributions of NOX, XO, and mitochondrial
sources of ROS to increased ET-1-mediate vasoconstriction following E-IH.

Effects of Inhibition of NOX on ET-1-Induced Vasoconstrictor Reactivity
Examination of the role of NOX in mediating elevated ET-1-induced
vasoconstriction after E-IH was accomplished by inhibiting NOX1/2 with apocynin (30
μM, Sigma). Unpublished studies from our laboratory indicate that this concentration of
apocynin selectively attenuates pulmonary vasoconstrictor reactivity in arteries from CH
rats. Apocynin was added to the vessel superfusate following the fura-2 loading and
maintained in the solution for the remainder of the experiment. Although concerns have
been raised about the selectivity of apocynin for inhibition of NOX (Heumuller et al.,
2008), a recent study found that apocynin inhibits the acute hypoxia-induced increase in
NOX activity and DCF fluorescence in PASMCs to a similar degree as genetic knockout
of the p47phox subunit (Rathore et al., 2008). ET-1-induced vasoconstrictor and VSM
Ca2+ responses were assessed as described above.
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Effects of Inhibition of Xanthine Oxidase on ET-1-Induced Vasoconstriction
The role of XO in mediating augmented ET-1-induced vasoconstrictor reactivity
following E-IH was examined by inhibiting XO with allopurinol (100 μM, Sigma)
(Massey et al., 1970). Following fura-2 loading and rinsing, allopurinol was added to the
bath solution and kept for the remainder of the experiment. Vasoconstrictor and VSM
[Ca2+]i responses to ET-1 were assessed as above.

Effects of Inhibition of Mitochondrial ROS Generation on ET-1-Induced Vasoconstriction
Responses to ET-1 were assessed in the presence of the specific mitochondrial
ROS scavenger mito-carboxy proxyl (MITO-CP, kindly provided by Navdeep Chandel,
Northwestern University). This mitochondrial-targeted nitroxyl facilitates dismutation of
superoxide as well as mitigating H2O2-induced cell apoptosis (Dhanasekaran et al.,
2005). MITO-CP (0.5 μM) was added to the artery superfusate following fura-2 loading
and equilibration. A recirculating system was used and the drug was maintained in the
solution during the addition of increasing concentrations of ET-1 (as described above).
Confirmatory experiments using the mitochondrial complex I inhibitor rotenone (10 μM,
Sigma) were also conducted. This concentration of rotenone has been used to inhibit
hypoxia-induced O2- generation in PASMC (Wang et al., 2007).

Rotenone was

administered during fura-2 loading, the subsequent rinse and during ET-1 exposure,
because rotenone is a reversible inhibitor of complex I. Vasoconstrictor and VSM Ca2+
responses were assessed in response to ET-1 as above.

63

Specific Aim 4.4 - Determine the effect of E-IH on arterial ROS levels under basal and
stimulated conditions.
Dihydroethidium (DHE, Molecular Probes) was used to evaluate effects of E-IH
on basal and ET-1-induced ROS production in isolated, pressurized pulmonary arteries.
DHE is cell permeant and in the presence of O2-, it is converted to the fluorescent
products ethidium and 2-hydroxyethidium (Dikalov et al., 2007;Jernigan et al.,
2008;Zhao et al., 2005). Pulmonary arteries were isolated, cannulated and endotheliumdisrupted as described above, with the exception of the makeup of the buffer. HEPESbased PSS (in mM, 130 NaCl, 4 KCl, 1.2 MgSO4, 4 NaHCO3, 1.8 CaCl2, 10 HEPES, 1.18
KH2PO4, 6 glucose, and 0.03 EDTA, pH adjusted to 7.4 with NaOH). A HEPES-based
PSS was used to maintain physiological pH during dissection since the solution was not
aerated with the 10% O2, 6% CO2, balance N2 gas mixture used for vasoreactivity
protocols. Following 30-min equilibration, the pressurized pulmonary arteries were
loaded with DHE (10 μM DHE and 0.02% pluronic acid). Vessels were incubated in this
solution for 30 min at room temperature in the dark and then rinsed for 5 min with PSS to
wash out excess dye.

We obtained fluorescent images using a standard

tetramethylrhodamine isothiocyanate (TRITC) filter (excitation ~550 nm and emission
~600 nm). Basal fluorescence was measured at 1 frame/ min for ~5 min. ET-1 (10-8 M)
was added to the superfusate and DHE fluorescence was monitored for 10 min. Images
were generated with a CCD camera (Hamamatsu Orca R2) and processed with Andor IQ
1.9 software. Normalized fluorescence intensity is defined as background-subtracted
mean intensity of grey-scale values for defined regions of interest, which were constant
between all vessels. In separate experiments, vessels were pretreated with tiron (10 mM)
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before (30 min) and during DHE loading and throughout the experiment. In addition, a
group of vessels was treated with myr-PKC (10 μM) before (30 min) and during DHE
loading.

Specific Aim 4.5 - Assess the role of ROS-dependent PKC activation in enhanced ET-1dependent vasoconstriction following E-IH.

Effect of Combined ROS Scavenging and PKC Inhibition on Vasoconstrictor Reactivity to
ET-1
To address whether ROS and PKC contribute to enhanced ET-1-induced
vasoconstriction after E-IH through a common signaling pathway, vasoconstrictor and
VSM Ca2+ responses to ET-1 were assessed during combined O2- scavenging and PKC
inhibition using a tiron/Ro 31-8220 cocktail.

Effect of Combined PKCα/β Inhibition on Basal and ET-1-Stimulated ROS Production
To determine whether PKCα/β mediate ET-1 induced O2- generation following EIH, basal and ET-1-stimulated DHE fluorescence were measured in the presence of a
PKCα/β inhibitor. Vessels were incubated with myr-PKC (10 μM) 30 min prior to DHE
loading and during DHE loading. Because the cell permeant myristoylate group of myrPKC is cleaved once myr-PKC is internalized into the cell, rinsing the inhibitor should
not decrease its concentration in the cell.
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Calculations and Statistics
All data were expressed as means ± SE and values of n refer to the number of
animals in each group. Two-way ANOVA was used to compare vasoconstriction and
VSM Ca2+ data between groups. Two-way repeated measures ANOVA was used to
compare basal vs. ET-1-stimulated DHE fluorescence values.

If differences were

detected by ANOVA, individual groups were compared with the Student-Newman-Keuls
test. A probability of P<0.05 was accepted as significant for all comparisons.
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CHAPTER III

RESULTS

Specific Aim 1:

Compare effects of E-IH and H-IH on indices of PH and

vasoconstrictor reactivity.

Specific Aim 1.1 - Compare effects of E-IH and H-IH on arterial blood gases.
To characterize the cyclical changes in arterial PO2, PCO2 and pH that occur during
H-IH and E-IH exposure, we measured arterial blood gases on the first day of cycling in
both groups of rats. Prior to the first hypoxic stimulus, PO2 values were not different
between H-IH and E-IH groups (Figure 5, Pre). Both H-IH and E-IH rats showed the
anticipated decrease in PO2 during hypoxic exposure (Figure 5, Nadir) and both groups
recovered to pre stimulus PO2 values during the air flush (Figure 5, Post). In addition,
PCO2 values were not different between groups before exposure to hypoxia and CO2
(Figure 6, Pre), however, H-IH animals were hypocapnic while E-IH animals remained
eucapnic during nadir O2 and peak CO2 exposures (Figure 6, Post). During the air flush,
H-IH animals remained slightly hypocapnic (Figure 6, Post).
measurements were inversely related to PCO2 (Figure 7).

As expected, pH

Based on these data, we

designated our treatments H- IH and E- IH.
At the end of four weeks of E-IH exposure, arterial blood samples were taken
from Wistar rats as above to determine whether chronic IH results in any long term
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Figure 5. Arterial PO2 measurements from Sprague Dawley rats before (Pre)
during (Nadir) and after (Post) acute H-IH or E-IH exposure. Values are means ±
SE of n= 4-5 rats/treatment. * P < 0.05 vs. respective pre- exposure value. # P <
0.05 vs. nadir value.
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Figure 6. Arterial PCO2 measurements from Sprague Dawleny rats before (Pre)
during (Nadir) and after (Post) acute H-IH or E-IH exposure. Values are means ±
SE of n= 4-5 rats/treatment. * P < 0.05 vs. respective pre exposure value. # P <
0.05 vs. nadir value. τ P < 0.05 vs. H-IH.
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Figure 7. Arterial pH measurements from Sprague Dawley rats before (Pre) during
(Nadir) and after (Post) acute H-IH or E-IH exposure Values are means ± SE of n=
4-5 rats/treatment. * P < 0.05 vs. respective pre exposure value. # P < 0.05 vs.
nadir value. τ P < 0.05 vs. H-IH.

70

adaptative changes in arterial blood gases. We found that PO2 (Figure 8), PCO2 (Figure
9), and pH (Figure 10) measurements reflected values before chronic E-IH exposure. At
the nadir of O2, PO2 was less than under resting conditions and this value recovered to
pre-exposure values during the air flush. PCO2 did not change during exposure to IH in
these 4 week E-IH rats. Similarly, arterial pH remained constant during cycling.

Specific Aim 1.2 - Assess effects of E-IH and H-IH on right ventricular hypertrophy.
Right Ventricular Hypertrophy in 2 Week IH Sprague Dawley Rats
Consistent with our hypothesis, right ventricle to total ventricle weight ratios were
significantly greater following 2 weeks of H-IH compared to Sham controls, and this
difference was not present following E-IH (Figure 11A). Similarly, only H-IH increased
the RV/BW ratio (Figure 12A).

There were no differences between groups in left

ventricle plus septal weight normalized to body weight.

Right Ventricular Hypertrophy in 4 Week IH Wistar Rats
In Wistar rats exposed to 4 weeks of IH, right ventricular hypertrophy developed
regardless of CO2 supplementation. Figure 11B shows elevated RV/T in both H-IH and
E-IH rats. Consistent with these findings, RV/BW ratio was greater in both H-IH and EIH rats than Sham rats (Figure 12B). Both H-IH and E-IH exposure attenuated weight
gain compared to Sham animals (Table 2). Because E-IH elicited RV hypertrophy in
Wistar rats and because E-IH more closely approximates the blood gas changes in
patients with SA, 4 week E-IH Wistar rats were studied for all experiments in Specific
Aims 2-4.
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Figure 8. Arterial PO2 following 4 week E-IH exposure in Wistar rats before (Pre),
during (Nadir) and after (Post) one E-IH cycle. Values are means ± SE of n= 4 rats.
* P < 0.05 vs. respective pre- cycling value.
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Figure 9. Arterial PCO2 following 4 week E-IH exposure in Wistar rats before
(Pre), during (Nadir) and after (Post) one E-IH cycle. Values are means ± SE of n=
3 rats. There are no differences.
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Figure 10. Arterial blood gas pH following 4 week E-IH exposure in Wistar rats
before (Pre), during (Nadir) and after (Post) one E-IH cycle. Values are means ± SE
of n= 3 rats. There are no differences.
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Figure 11. Ratios of right ventricle (RV) to total ventricle (T) weight in (A) 2 week
Sprague Dawley and (B) 4 week Wistar Sham-treated, H-IH and E-IH rats. Values
are means ± SE of n = 7-23rats/group. *P < 0.05 vs. Sham. # P < 0.05 vs. H-IH.
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Figure 12. Ratios of right ventricle (RV) to body weight (BW) in (A) 2 week
Sprague Dawley and (B) 4 week Wistar Sham-treated, H-IH and E-IH rats. Values
are means ± SE of n = 7-23rats/group. *P < 0.05 vs. Sham.

76

Table 2. Left ventricle + septum heart weight and pre and post exposure body weights in
sham-treated, hypocapnic intermittently hypoxic (H-IH) and eucapnic intermittently
hypoxic (E-IH) Wistar rats.
Group
BW (Pre)
BW (Post)
LV+S/BW
n
Sham
7
253 ± 11
392 ± 10*
1.91 ± 0.04
H-IH
7
246 ± 12
309 ± 14*#
2.14 ± 0.05
8
E-IH
2.03 ± 0.07
244 ± 12
324 ± 12*#
BW (Pre and Post) denote values before and after, respectively, exposure to Sham or IH.
Values are means ± SE. n, number of rats. *P<0.05 vs. pre-exposure value. #P<0.05 vs.
Sham post-exposure BW.
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Specific Aim 1.3 - Assess the degree of polycythemia resulting from E-IH and H-IH
exposure.
Two weeks of H-IH resulted in elevated hematocrit compared to Sham-treated
animals (Figure 13A). Two weeks E-IH elicited a modest increase in hematocrit that was
significantly lower than the H-IH group (Figure 13A). Four weeks exposure to H-IH
caused profound polycythemia in Wistar rats. However, this response was absent in 4
week E-IH Wistar rats (Figure 13B).

Specific Aim 1.4 – Compare pulmonary arterial remodeling responses to E-IH and H-IH.
Figure 14 illustrates percent wall thickness for pulmonary arteries with external
diameters of < 50 μm (Figure 14A) and 50-100 μm (Figure 14B) from Sprague Dawley
rats exposed to 2 weeks of Sham or IH treatment.

H-IH exposure increased wall

thickness compared to control groups in each range of vessel diameters. Prevention of
hypocapnia with supplemental CO2 prevented IH-induced arterial remodeling (Fig. 14).
These findings are consistent with effects of H-IH and E-IH on RV hypertrophy (Figures
11-12).

Specific Aim 1.5 - Assess effects of E-IH and H-IH on vasoconstrictor reactivity.
Vasoconstriction represents an important contribution to the development of PH.
CH augments vasoconstrictor reactivity to agonists such as U-46619 (Eichinger &
Walker, 1994;Resta & Walker, 1996), ET-1 (Jernigan et al., 2008), UTP (Jernigan et al.,
2004b;Rodat et al., 2007) and 5-HT (Rodat et al., 2007). However, effects of IH on
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Figure 13. Percent hematocrit in A) 2 week Sprague Dawley and B) 4 week
Wistar Sham-treated, H-IH and E-IH rats. Values are means ± SE of n = 7-10
rats/group. * P < 0.05 vs. Sham. # P < 0.05 vs. H-IH.
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Figure 14. Percent arterial wall thickness of pulmonary arteries with external
diameters of < 50 μm (A) and 50-100 μm (B) from Sham-treated, H-IH and E-IH
rats. Values are means ± SE of n = 4 rats/group. *P < 0.05 vs. Sham. #P < 0.05 vs.
H-IH.
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vasoconstrictor reactivity have not been well studied.

Given the markedly blunted

polycythemia and remodeling in E-IH rats compared to H-IH, despite RV hypertrophy,
we measured vasoconstrictor reactivity to various-receptor mediated agonists following 4
weeks IH exposure in Wistar rats.

Vasoconstrictor Reactivity to ET-1 Following IH in Isolated Pulmonary Arteries
To determine whether vasoconstrictor reactivity to ET-1 is augmented in
pulmonary arteries from E-IH animals and whether supplemental CO2 attenuates that
increase in reactivity, vasoconstrictor and VSM [Ca2+]i responses to ET-1 were assessed
in isolated, pressurized, arteries from Wistar rats exposed to 4 weeks of Sham, H-IH and
E-IH treatment. In order to assess effects of H-IH and E-IH on PA smooth muscle
function, all arteries were endothelium-disrupted. Vasoconstrictor responses were greater
in arteries from both H-IH and E-IH rats compared to Sham (Figure 15). However,
vasoconstriction to ET-1 was slightly blunted in arteries from E-IH compared to H-IH
rats (ET-1 10-9.5 and 10-9 M). Ca2+ responses were similar between all three groups. No
differences in basal inner diameter or F340/F380 were detected (Table 3). These data
suggest that both H-IH and E-IH increase ET-1-induced vasoconstriction via Ca2+
sensitization. All subsequent vasoconstrictor studies were performed only in arteries
from Sham and E-IH rats because E-IH more closely mimics blood gas conditions of SA
and is associated with increased agonist-induced vasoconstriction.

,
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Figure 15. A) Vasoconstrictor and B) VSM [Ca2+]i responses to ET-1 in vessels
from Sham, H-IH and E-IH rats. Values are means ± SE of n = 6-9 rats/group. *
P < 0.05 H-IH and E-IH vs. Sham. #P<0.05 H-IH vs. E-IH.
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Table 3. Basal inner diameter and VSM [Ca2+]i (F340/F380) in isolated, pressurized
pulmonary arteries from Sham, H-IH and E-IH rats.
F340/F380
Group
n
Inner Diameter (μm)
Sham
9
156 ± 14
0.77 ± 0.05
H-IH

155 ± 10

0.74 ± 0.07

6

E-IH

173 ± 8

0.75 ± 0.09

9

Values are means ± SE. n, number of rats. There are no significant differences.
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Vasoconstrictor Reactivity to UTP in Isolated Pulmonary Arteries
To address whether the increase in ET-1-induced vasoconstrictor reactivity following EIH reflects a generalized increase in agonist-induced vasoconstriction, vasoconstrictor
reactivity to UTP was assessed in Sham and E-IH vessels. Responses to UTP were
greater in pulmonary arteries E-IH rats compared to Sham controls (Figure 16).
However, Ca2+ responses were again similar between groups.

Vasoconstrictor Reactivity to 5-HT in Isolated Pulmonary Arteries
Similar to effects of E-IH on responses to ET-1 and UTP, vasoconstrictor
reactivity to 5-HT was elevated in pulmonary arteries from Wistar rats exposed to E-IH
compared to those of Sham animals (Figure 17). VSM Ca2+ responses were modest and
were not different between Sham and E-IH vessels. Together, these data suggest that EIH causes a generalized increase in agonist-mediated vasoconstriction through increased
VSM Ca2+ sensitivity.

Summary of Results for Specific Aim 1
• Exposure of rats to IH results in hypoxemia. IH without CO2 supplementation causes
hypocapnia and alkalosis. However, CO2 supplementation results in hypoxemia and
maintained eucapnia.
• Two weeks of H-IH but not E-IH causes right ventricular hypertrophy in Sprague
Dawley rats.

In contrast, both H-IH and E-IH (4 weeks) elicit right ventricular

hypertrophy in Wistar rats.
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Figure 16. A) Vasoconstrictor and B) VSM [Ca2+]i responses to UTP in vessels
from Sham and E-IH Wistar rats. Values are means ± SE of n = 6-7 rats/group.
*P< 0.05 vs. Sham.
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Figure 17. A) Vasoconstrictor and B) VSM [Ca2+]i responses to 5-HT in vessels
from Sham and E-IH rats. Values are means ± SE of n = 4 rats/group. * P < 0.05
vs. Sham.
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•

H-IH increases hematocrit in both Sprague Dawley rats (2 wk exposure) and Wistar
rats (4 week exposure).

In contrast, rats exposed to E-IH do not develop

polycythemia.
•

H-IH causes a greater degree of pulmonary arterial remodeling than E-IH in both
sizes of pulmonary arteries examined (<50 μm and 50-100 μm).

•

E-IH increases vasoconstrictor reactivity to ET-1, UTP and 5-HT in pulmonary
arteries without increasing associated Ca2+ responses.

Conclusion
E-IH most closely mimics arterial blood gases of SA patients and elicits RV hypertrophy
in Wistar rats. In addition, E-IH increases pulmonary artery vasoconstrictor reactivity,
likely through a Ca2+ sensitization mechanism.
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Specific Aim 2: Assess the role of ROK in mediating right ventricular hypertrophy
and enhanced agonist-induced pulmonary vasoconstriction following E-IH.
ROK mediates a major agonist-induced signaling pathway in pulmonary VSM.
Also, CH increases ROK-dependent pulmonary VSM Ca2+ sensitization, and ROK plays
a role in CH-induced PH. However, whether ROK is involved in the development of EIH-induced PH, and whether a similar ROK signaling mechanism mediates augmented
pulmonary vasoconstrictor reactivity in E-IH vessels has not been determined.

Specific Aim 2.1 - Evaluate the contribution of ROK to E-IH-induced RV hypertrophy.
Effect of Chronic ROK Inhibition on the Right Ventricular Hypertrophic Response to EIH.
Although RV/T and RV/BW tended to be lower in E-IH rats treated with fasudil
(30 mg/kg/day for 4 weeks) compared to vehicle-treated animals, this did not achieve
statistical significance (Fig 18). These results suggest that ROK does not contribute
substantially to E-IH-induced RV hypertrophy and associated PH.

Specific Aim 2.2 – Determine the role of ROK in mediating enhanced ET-1-induced
vasoconstrictor reactivity following E-IH.
Effect of ROK Inhibition on ET-1-Induced Pulmonary Vasoconstriction and Ca2+
Responses in Isolated Pulmonary Arteries
Inhibition of ROK with fasudil (10 μM) did not inhibit vasoconstrictor reactivity
to ET-1 in vessels from either Sham or E-IH rats (Figure 19). In addition, there was no
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Figure 18. A) RV/T and B) RV/BW from E-IH animals treated with vehicle or
fasudil (30 mg/kg/day) for 4 weeks. Data are means ± SE of n= 4-5/group. There
are no significant differences.
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Figure 19. A) Vasoconstrictor and B) VSM [Ca2+]i responses to ET-1 in the
presence and absence of the ROK inhibitor fasudil (10 μM). (*P<0.05 E-IH vs.
Sham; ‡P<0.05 Sham + fasudil vs. E-IH + fasudil; #P<0.05 E-IH vs. E-IH +
fasudil) Data are means ± SE of n= 6-9/group.
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effect of ROK inhibition on VSM Ca2+ responses to ET-1, suggesting that ROK does not
mediate the ET-1-induced response in vessels from either Sham or E-IH rats. Fasudil did
not alter basal VSM [Ca2+]i or inner diameter (Table 4).

Summary of Results for Aim 2
•

RV/T and RV/BW were not different between vehicle-treated and fasudil-treated EIH rats.

•

Fasudil did not attenuate enhanced ET-1-induced vasoconstriction following E-IH.

Conclusion
E-IH-induced right ventricular hypertrophy and enhanced vasoconstrictor reactivity to
ET-1 are independent of ROK.
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Table 4. Basal inner diameters and VSM [Ca2+]i (F340/F380) in vehicle or fasudilpretreated arteries from Sham and E-IH rats
Group/Treatment
Inner Diameter
(F340/F380)
Sham Vehicle
156 ± 14
0.77 ± 0.05
E-IH Vehicle
173 ± 8
0.75 ± 0.09
Sham Fasudil
0.69 ± 0.04
122 ± 15
E-IH Fasudil
166 ± 19
0.68 ± 0.07
Values are means ± SE. n, number of rats. There are no significant differences.
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n
9
9
6
6

Specific Aim 3: Assess the contribution of PKC to increased agonist-mediated
vasoconstriction following E-IH.

Specific Aim 3.1 - Determine the role of specific PKC isoforms in mediating enhanced
ET-1-induced vasoconstriction following E-IH.
Based on findings in Specific Aim 2 that increased ET-1-dependent constriction
after E-IH is mediated by Ca2+ sensitization, but not via ROK-dependent signaling, we
sought another mechanism by which E-IH might increase ET-1-induced vasoconstriction.
PKC is an alternative mediator of VSM Ca2+ sensitization and E-IH increases PKCdependent constriction in the systemic circulation (Allahdadi et al., 2008b). However,
effects of E-IH on PKC-dependent pulmonary vasoconstriction are unknown.

Effect of Generalized PKC Inhibition on ET-1-Induced Vasoconstriction
To validate the concentration of the general PKC inhibitor Ro 31-8220 used in the
present study, we assessed constrictions in pulmonary arteries to the PKC activator PMA
in the presence of vehicle and Ro 31-8220 (5 μM). PMA-induced vasoconstriction was
nearly abolished by this concentration of Ro 31-8220 (Figure 20). Ro 31-8220 attenuated
vasoconstrictor responses to ET-1 in both Sham and E-IH groups and normalized
responses between groups (Figure 21A). In addition, Ro 31-8220 blunted the Ca2+
responses to ET-1 in both Sham and E-IH arteries (Figure 21B). These findings suggest
that

PKC

is

involved

in

ET-1-induced
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Figure 20. Vasoconstrictor responses to the PKC activator PMA in the presence
of vehicle or the PKC inhibitor Ro 31-8220 (5 μM) in endothelium-disrupted
pulmonary arteries from control rats. Values are means ± SE of n = 3-4
rats/group. * P < 0.05 vs. vehicle.
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Figure 21. A) Vasoconstrictor and B) VSM [Ca2+]i responses to ET-1 in the
presence and absence of the PKC inhibitor Ro 31-8220 (5 μM). (*P<0.05 E-IH
vs. Sham; # P<0.05 E-IH vs. E-IH + Ro; †P<0.05 Sham vs. Sham + Ro) Data
are means ± SE of n= 4-9/group.
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mobilization in both Sham and E-IH groups and that PKC mediates the elevated
vasoconstrictor reactivity following E-IH.

Effect of Selective PKCα/β Inhibition on ET-1-Induced Vasoconstriction
To validate the concentration of the selective PKCα/β inhibitor myr-PKC used in
the present study, we assessed constrictions in pulmonary arteries to the PKC activator
PMA in the presence of vehicle and myr-PKC (10 μM). PMA-induced vasoconstriction
was significantly attenuated by this concentration of myr-PKC (Figure 22).
PKCα/β inhibition decreased ET-1-induced vasoconstriction in vessels from E-IH rats,
but was without effect on responses in arteries from Sham rats (Figure 23A). In addition,
PKCα/β inhibition normalized constrictions between Sham and E-IH groups.
Furthermore, Ca2+ responses to ET-1 were unaltered by myr-PKC in either group (Figure
23B), suggesting that PKCα/β contribute to elevated ET-1-induced Ca2+ sensitization
after E-IH.

ET-1-Induced Vasoconstriction in the Presence of a PKCδ Inhibitor
The PKCδ inhibitor rottlerin (3 μM) attenuated PMA-induced constriction in
control arteries (Figure 24). Therefore, this concentration of rottlerin was used to inhibit
PKCδ in Sham and E-IH arteries but did not decrease vasoconstrictor reactivity to ET-1
following E-IH (Figure 25A). In fact, constriction was significantly greater in E-IH
vessels in the presence of rottlerin (at 10-10.5 - 10-10 M ET-1), and this was associated with
an increased Ca2+ response in the presence of rottlerin at lower concentrations of ET-1
(Figure 25B).
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Figure 22. Vasoconstrictor responses to the PKC activator PMA in the presence
of vehicle or the PKCα/β inhibitor myr-PKC (10 μM) in endothelium-disrupted
pulmonary arteries from control rats. Values are means ±SE of n=4-5 rats/group
*P<0.05 vs. vehicle.
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Figure 23. A) Vasoconstrictor and B) VSM [Ca2+]i responses to ET-1 in the
presence and absence of the PKCα/β inhibitor myr-PKC (10 μM). (*P<0.05 EIH vs. Sham; #P<0.05 IH vs. E-IH + myr-PKC) Data are means ± SE of n= 56/group.
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Figure 24. Vasoconstrictor responses to the PKC activator PMA in the presence
of vehicle or the PKCδ inhibitor Rottlerin (3 μM) in endothelium-disrupted
pulmonary arteries from control rats. Values are means ± SE of n = 4 rats/group.
* P < 0.05 vs. vehicle.
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Figure 25. A) Vasoconstrictor and B) VSM [Ca2+]i responses to ET-1 in
pulmonary arteries from Sham and E-IH rats in the presence and absence of the
PKCδ inhibitor rottlerin (3 μM). (*P<0.05 E-IH vs. Sham; ‡P<0.05 Sham +
rottlerin vs. E-IH + rottlerin; #P<0.05 E-IH vs. E-IH + rottlerin) Data are means
± SE of n= 5/group.
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In the presence of the vehicle for rottlerin (ethanol) there was a slightly attenuated Ca2+
response in vessels from E-IH animals compared to Sham, but this was associated with
the same degree of constriction in response to ET-1 in both groups. The effect of
rottlerin to increase ET-1-dependent increases in Ca2+ in the E-IH group indicates a
possible role for PKCδ to antagonize agonist-induced VSM Ca2+ mobilization after E-IH.
Overall, these results suggest that PKCδ does not mediate enhanced ET-1-induced
vasoconstriction
There were no differences in basal arterial inner diameter between groups. Basal
VSM [Ca2+]i (F340/F380) was similar between Sham and E-IH for all drugs and vehicles,
except in the presence of the vehicle for rottlerin (ethanol), Sham arteries showed a larger
basal VSM [Ca2+]i (Table 5). In situ fura-2 calibrations were performed to evaluate
potential autofluorescence of drugs or effects of drugs on the affinity of fura-2 for Ca2+.
Ro 31-8220, myr-PKC and rottlerin did not alter low or high in situ calibrations (Table
6).

Specific Aim 3.2 - Examine the effect of E-IH on pulmonary arterial PKC expression.
Effects of E-IH on PKC mRNA Expression
Based on findings in Specific Aim 3.1 that E-IH increases PKC-dependent
vasoconstrictor reactivity, we sought to determine whether E-IH increases PKC
expression to mediate enhanced PKC-dependent signaling. PKCα and β mRNA levels in
intrapulmonary arteries were measured by real time PCR. E-IH did not significantly alter
either PKCα or PKCβ mRNA levels (Figure 26).
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Table 5. Basal inner diameters and VSM [Ca2+]i (F340/F380) in vehicle or Ro 31-8220,
myr-PKC- or Rottlerin- pretreated arteries from Sham and E-IH rats
F340/F380
Group/Treatment
n
Inner Diameter (μm)
Sham + Vehicle for
6
125 ± 15
0.72 ± 0.06
Ro and myr-PKC
E-IH + Vehicle for
4
150 ± 14
0.78 ± 0.10
Ro and myr-PKC
8
Sham + Ro
139 ± 8
0.84 ± 0.06
E-IH + Ro

151 ± 15

0.83 ± 0.07

9

Sham + myr-PKC

140 ± 24

0.76 ± 0.04

5

E-IH + myr-PKC

161 ± 23

0.65 ± 0.04

6

Sham + Vehicle for
Rottlerin
E-IH + Vehicle for
Rottlerin
Sham + Rottlerin

122 ± 17

0.89 ± 0.06

5

145 ± 23

0.75 ± 0.03*

5

141 ± 14

0.77 ± 0.04

5

E-IH + Rottlerin

147 ± 16

0.72 ± 0.02

5

Values are means ± SE. n=number of rats. *P<0.05 vs. Sham + Vehicle for Rottlerin.
Ro, Ro 31-8220.
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Table 6. In situ fura-2 calibration values in vehicle or Ro 31-8220, myr-PKC- or
Rottlerin- pretreated arteries from Sham and E-IH rats
Group/Treatment
Low Cal (F340/F380)
High Cal (F340/F380)
Sham + Vehicle for
0.58 ± 0.02
1.61 ± 0.10
Ro 31-8220 and
myr-PKC
E-IH + Vehicle for
0.55 ± 0.02
1.60 ± 0.12
Ro 31-8220 and
myr-PKC
Sham + Ro 31-8220
0.60 ± 0.03
1.25 ± 0.04

n
6
4

6

E-IH + Ro 31-8220

0.57 ± 0.02

1.30 ± 0.09

7

Sham + myr-PKC

0.55 ± 0.02

1.54 ± 0.22

4

E-IH + myr-PKC

0.51 ± 0.01

1.33 ± 0.10

7

Sham + Vehicle for
Rottlerin

0.56 ± 0.01

1.88 ± 0.22

4

E-IH + Vehicle for
Rottlerin

0.59 ± 0.05

1.77 ± 0.03

3

Sham + Rottlerin

0.62 ± 0.03

1.62 ± 0.12

5

E-IH + Rottlerin

0.56 ± 0.02

1.60 ± 0.08

6

Values are means ± SE. n= number of rats. There are no significant differences.
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Figure 26. Pulmonary arterial A) PKCα and B)PKCβ mRNA levels determined
by real time PCR for in from Sham and E-IH rats. Data are means ± SE of n=
6/group. There are no significant differences.
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Effects of E-IH on PKC Protein Expression
Consistent with mRNA results, E-IH did not alter pulmonary arterial
PKCα (Figure 27), PKCβΙ or PKCβΙΙ (Figure 28) protein levels, as determined by
western blot analysis.
Summary of Results for Specific Aim 3
•

General PKC inhibition and PKCα/β inhibition prevent the enhanced ET-1-dependent
constriction following E-IH.

•

Pulmonary arterial PKCα/β mRNA and protein expression are not different between
Sham and E-IH.

Conclusion
Enhanced vasoconstrictor reactivity to ET-1 is dependent on PKCα/β, but this is not due
to an increase in protein expression.
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Figure 27. Western blotting data for PKCα in pulmonary arteries from Sham
and IH rats. Data are means ± SE of n= 3-4/group. There are no significant
differences.
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Figure 28. Western blot data for A) PKCβI and B)PKCβII in pulmonary
arteries from Sham and IH rats. Data are means ± SE of n= 4-8/group. There
are no significant differences.
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Specific Aim 4: Determine the contribution of ROS to the development of right
ventricular hypertrophy and enhanced agonist-induced vasoconstriction after E-IH.
Based on our findings in Specific Aim 3 that elevated agonist-induced
vasoconstriction after E-IH is mediated by PKC, and given the evidence that ROS can
activate PKC in PASMC (Rathore et al., 2008), we sought to address the role of ROS in
contributing to RV hypertrophy, PKC activation and enhanced agonist-induced
vasoconstriction.

Specific Aim 4.1 - Assess the role of ROS in mediating E-IH-induced right ventricular
hypertrophy.
To examine whether E-IH-induced RV hypertrophy is dependent on ROS
generation, we administered the SOD mimetic tempol (1 mM) in vivo to rats treated with
Sham or E-IH for 4 weeks. Following exposure to Sham or E-IH, right ventricles, left
ventricle + septum, and body weight were measured. Right ventricle/total ventricular
weight or body weight were calculated as indices of the degree of PH. Tempol treatment
prevented E-IH-induced right ventricular hypertrophy as assessed by RV/T (Figure 29)
and RV/BW (Table 7). Both Sham and E-IH tempol-treated rats gained weight over the 4
week treatment, however Sham rats gained more weight than E-IH rats.

This is

consistent with results from untreated rats (Table 2). There were no differences between
left ventricle + septum/ body weight between Sham and E-IH rats.
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Figure 29. Ratios of right ventricle (RV) to total ventricle (T) weight in 4 week
Wistar Sham and E-IH untreated or tempol-treated (1mM in the drinking water)
rats. Values are means ± SE of n = 4- rats/group. *P < 0.05 vs. Sham. #P < 0.05
vs. untreated E-IH.
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Table 7. Pre and post exposure body weights, right ventricle/body weight and left
ventricle + septum/body weight in tempol-treated Sham and E-IH rats.
Group/
Pre BW
Post BW
RV/BW
LV+S/BW
Treatment
(g)
(g)
(g/kg)
(g/kg)
Sham + Tempol
E-IH + Tempol

185 ± 5
184 ± 8

368 ± 11*
304 ± 10*#

0.55 ± .02
0.56 ± .02

2.06 ± .03
2.11 ± .04

n
4
4

Pre BW denotes body weight before Sham or E-IH treatment. Post BW denotes body
weight following 4 weeks of Sham or E-IH treatment. Values are means ± SE. n,
number of rats. *P<0.05 vs. pre-exposure value. #P<0.05 vs. Sham post-exposure BW.

110

Specific Aim 4.2 - Assess the role of O2- and H2O2 in mediating augmented ET-1induced vasoconstrictor reactivity following E-IH.
To determine whether augmented ET-1-induced vasoconstriction is mediated by
ROS, responses to ET-1 were assessed in the presence of the O2- scavenger tiron (10
mM).

As shown in Figure 30A, tiron prevented the increased vasoconstriction in

response to ET-1 in arteries from E-IH rats while having little effect on the Ca2+
response to ET-1 (Figure 30B). In addition, tiron normalized vasoconstrictor responses
between Sham and E-IH groups. Tiron did not alter basal arterial inner diameter, VSM
[Ca2+]i (Table 8), or in situ calibration values (Table 9).
To evaluate the potential contribution of H2O2 to augmented ET-1-induced
vasoconstriction after E-IH, vasoconstrictor and VSM Ca2+ responses to ET-1 were
assessed in the presence of the membrane permeable H2O2 scavenger, PEG-catalase.
PEG-catalase did not alter vasoconstrictor responses to ET-1 in either group (Figure 31A)
except for a slight augmentation at one concentration of ET-1 (10-11 M) in E-IH arteries.
Ca2+ responses were similarly unaltered by PEG-catalase (Figure 31B). Basal inner
diameter and F340/F380 (Table 8) and in situ fura-2 calibration values (Table 9) were
unaltered by PEG-catalase, although basal F340/F380 was lower in E-IH arteries in the
presence of PEG-catalase compared to Sham arteries + PEG-catalase (Table 8). These
data suggest that H2O2 does not mediate the elevated ET-1-induced vasoconstriction after
E-IH.
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Figure 30. A) Vasoconstrictor and B) VSM [Ca2+]i responses in the presence
and absence of the ROS scavenger tiron (10 mM). (*P<0.05 E-IH vs. Sham;
#P<0.05 E-IH vs. E-IH + tiron) Data are means ± SE of n= 5-9/group.
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Table 8. Basal inner diameter and VSM [Ca2+]i (F340/F380) in all vehicle- and drugtreated arteries in Specific Aim 4 from Sham and E-IH rats.
F340/F380
Group/Treatment
n
Inner Diameter (μm)
Sham + Vehicle for Tiron
6
134 ± 25
0.71 ± 0.06
E-IH + Vehicle for Tiron

158 ± 20

0.85 ± 0.10

5

Sham + Tiron

128 ± 12

0.84 ± 0.06

8

E-IH + Tiron

143 ± 11

0.94 ± 0.05

9

Sham + Vehicle for MITOCP
E-IH + Vehicle for MITOCP
Sham + MITO-CP

116 ± 14

0.74 ± 0.06

5

144 ± 10*

0.71 ± 0.04

5

114 ± 8

0.92 ± 0.07

4

E-IH + MITO-CP

118 ± 12

0.80 ± 0.06

5

Sham + Vehicle for PEGcatalase and Allopurinol
E-IH + Vehicle for PEGcatalase and Allopurinol
Sham + PEG-catalase

98 ± 3

0.90 ± 0.11

4

181 ± 12†

0.85 ± 0.06

5

139 ± 14

0.94 ± 0.06

5

E-IH + PEG-catalase

124 ± 14

0.81 ± 0.08**

5

Sham + Allopurinol

93 ± 10

0.86 ± 0.05

3

E-IH + Allopurinol

148 ± 18#

0.77 ± 0.19

5

Sham + Vehicle for
Apocynin and Rotenone
E-IH + Vehicle for
Apocynin and Rotenone
Sham + Apocynin

120 ± 22

0.88 ± 0.07

4

145 ± 28

0.88 ± 0.06

4

125 ± 4

0.71 ± 0.04

5

E-IH + Apocynin

156 ± 5

0.94 ± 0.10

5

Sham + Rotenone

147 ± 20

0.72 ± 0.07

4

E-IH + Rotenone

158 ± 18

0.78 ± 0.05

4
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Sham + Vehicle for Ro +
Tiron/ myr-PKC + Tiron
E-IH + Vehicle for Ro +
Tiron/ myr-PKC + Tiron
Sham + Ro + Tiron

125 ± 15

0.72 ± 0.06

6

150 ± 14

0.78 ± 0.10

4

181 ± 8‡

0.85 ± 0.07

5

E-IH + Ro + Tiron

170 ± 10

0.88 ± 0.06

5

Sham + myr-PKC + Tiron

175 ± 12‡

0.74 ± 0.05

4

E-IH + myr-PKC + Tiron

152 ± 17

0.71 ± 0.04

5

Values are means ± SE. n, number of rats. *P<0.05 vs. Sham + Vehicle for MITO-CP.
†P<0.05 vs. Sham + Vehicle PEG-catalase and Allopurinol. # P<0.05 vs. Sham +
Allopurinol. **P<0.05 vs. Sham + PEG-catalase. ‡P<0.05 vs. Sham + Vehicle for Ro +
Tiron/ myr-PKC + Tiron.
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Table 9. In situ fura-2 calibration values
Low Cal (F340/F380)
Sham + Vehicle for Tiron
0.56 ± 0.03

High Cal (F340/F380)
1.51 ± 0.12

n
5

E-IH + Vehicle for Tiron

0.54 ± 0.02

1.48 ± 0.07

5

Sham + Tiron

0.55 ± 0.03

1.52 ± 0.11

7

E-IH + Tiron

0.54 ± 0.02

1.48 ± 0.07

8

Sham + Vehicle for PEGcatalase and Allopurinol
E-IH + Vehicle for PEGcatalase and Allopurinol
Sham + PEG-catalase

0.63 ± 0.08

1.83 ± 0.25

4

0.64 ± 0.05

1.64 ± 0.16

5

0.63 ± 0.02

1.78 ± 0.19

5

E-IH + PEG-catalase

0.63 ± 0.03

1.56 ± 0.14

5

Sham + Allopurinol

0.75 ± 0.03

1.73 ± 0.12

3

E-IH + Allopurinol

0.63 ± 0.02

1.65 ± 0.11

5

Sham + Vehicle for
Apocynin and Rotenone
E-IH + Vehicle for Apocynin
and Rotenone
Sham + Apocynin

0.63 ± 0.05

1.73 ± 0.19

4

0.62 ± 0.03

1.94 ± 0.05

4

0.59 ± 0.08

1.88 ± 0.19

5

E-IH + Apocynin

0.59 ± 0.04

1.85 ± 0.25

4

Sham + Rotenone

0.76 ± 0.04

2.23 ± 0.23

4

E-IH + Rotenone

0.79 ± 0.06

2.47 ± 0.12

3

Sham + Vehicle for MITOCP
E-IH + Vehicle for MITO-CP

0.57 ± 0.02

1.58 ± 0.14

4

0.63 ± 0.02#

1.56 ± 0.09

5

Sham + MITO-CP

0.63 ± 0.02*

2.12 ± 0.01*

4

E-IH + MITO-CP

0.59 ± 0.01

1.60 ± 0.08 **

4

Values are means ± SE. n, number of rats. *P<0.05 vs. corresponding vehicle. .
#P<0.05 vs. Sham + vehicle for MITO-CP. **P<0.05 vs. Sham + MITO-CP.
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Figure 31. A) Vasoconstrictor and B) VSM [Ca2+]i responses in the presence
and absence of PEG-catalase (250 U/ml). (*P<0.05 E-IH vs. Sham; #P<0.05 EIH vs. E-IH + PEG-catalase; ‡P<0.05 Sham + PEG-catalase vs. E-IH + PEGcatalase) Data are means ± SE of n= 4-5/group.

116

Specific Aim 4.3 - Evaluate the relative contributions of NOX, XO, and mitochondrial
sources of ROS to increased ET-1-mediated vasoconstriction following E-IH.
Effects of Inhibition of NOX on ET-1-Induced Vasoconstriction
In the presence of apocynin, which inhibits NOX1/2 isoforms, the elevated
vasoconstriction to ET-1 in E-IH vessels persists (Figure 32A). Furthermore, apocynin
had no significant effect on ET-1-induced Ca2+ responses (Figure 32B), except for a
slight decrease in the Ca2+ response in E-IH vessels at one concentration of ET-1 (10-10
M). These data suggest that E-IH-induced increases in vasoreactivity to ET-1 are NOXindependent. Basal inner diameter and F340/F380 (Table 8) and in situ calibrations (Table
9) were not different between groups.

Effects Xanthine Oxidase Inhibition on ET-1-Induced Vasoconstriction
XO inhibition did not decrease either ET-1-induced constriction (Figure 33A) or
Ca2+ responses (Figure 33B) in E-IH vessels, indicating that ET-1-induced
vasoconstriction following E-IH is independent of XO-derived O2-. Furthermore, there
was no effect of allopurinol on either vasoconstrictor or VSM [Ca2+]i responses in Sham
vessels. Allopurinol did not alter basal inner diameter, F340/F380 (Table 8) or in situ
calibrations (Table 9).

Effects of Mitochondrial ROS Scavenging on ET-1-Induced Vasoconstriction
MITO-CP substantially inhibited vasoconstriction in arteries from E-IH rats,
while having minimal effects in the Sham group. Furthermore, mitochondrial ROS
scavenging resulted in normalization of reactivity between groups (Figure 34A). This
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Figure 32. A) Vasoconstrictor and B) VSM [Ca2+]i responses in the presence
and absence of the NADPH oxidase inhibitor apocynin (30 μM). (*P<0.05 E-IH
vs. Sham; #P<0.05 E-IH vs. E-IH + apocynin; ‡ P<0.05 E-IH + apocynin vs.
Sham + apocynin) Data are means ± SE of n= 4-5/group.
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Figure 33. A) Vasoconstrictor and B) VSM [Ca2+]i responses in the presence and
absence of the xanthine oxidase inhibitor allopurinol (100 μM). (*P<0.05 E-IH
vs. Sham; #P<0.05 E-IH vs. E-IH + allopurinol; ‡P<0.05 Sham + allopurinol vs.
E-IH + allopurinol) Data are means ± SE of n= 3-5/group.
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Figure 34. A) Vasoconstrictor and B) VSM [Ca2+]i responses in the presence
and absence of the mitochondrial ROS scavenger MITO-CP (0.5 μM). (*P<0.05
E-IH vs. Sham; #P<0.05 E-IH vs. E-IH + MITO-CP; †P<0.05 Sham vs. Sham +
MITO-CP) Data are means ± SE of n= 4-5/group.
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vasoconstriction by MITO-CP in E-IH arteries was associated with a tendency for a
lesser Ca2+ response to ET-1, which did not achieve statistical significance (Figure34B).
MITO-CP significantly attenuated ET-1-dependent increases in VSM [Ca2+]i in Sham
arteries at the highest concentrations of ET-1 (10-8-10-7M). In the presence of the vehicle
for MITO-CP (DMSO) basal inner diameter was greater in the E-IH group (Table 8).
Basal F340/F380 was not different between Sham and E-IH and was not altered by MITOCP. The low in situ calibration was greater in E-IH vehicle versus Sham vehicle group,
whereas in the presence of MITO-CP, the low calibration value was less in the E-IH
group. The high in situ calibration value was increased by MITO-CP in the Sham group
and was greater in Sham vessels in the presence of MITO-CP versus E-IH vessels treated
with MITO-CP (Table 9).
To confirm the effect of MITO-CP on vasoconstrictor responses to ET-1,
mitochondrial ROS generation was also inhibited with the mitochondrial complex I
inhibitor rotenone. Rotenone profoundly attenuated vasoconstrictor reactivity to ET-1 in
E-IH vessels while decreasing vasoconstriction to ET-1 only at one concentration (10-9.5
M) in Sham arteries. In addition, rotenone normalized responses between groups (Figure
35A). Surprisingly, rotenone increased Ca2+ responses to ET-1 in both groups (Figure
35B). Basal inner diameter and F340/F380 were not different in arteries treated with
rotenone or its vehicle (Table 8). Rotenone had no effect on in situ fura-2 calibrations
(Table 9).
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Figure 35. A) Vasoconstrictor and B) VSM [Ca2+]i responses in the presence
and absence of the mitochondrial complex I inhibitor rotenone (10 μM).
(*P<0.05 E-IH vs. Sham; #P<0.05 E-IH vs. E-IH + rotenone; †P<0.05 Sham vs.
Sham + rotenone; ‡P<0.05 Sham + rotenone vs. E-IH + rotenone) Data are
means ± SE of n= 4-5/group.
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Specific Aim 4.4 - Determine the effect of E-IH on pulmonary arterial ROS levels under
basal and stimulated conditions.
We evaluated effects of E-IH on basal and ET-1-induced DHE fluorescence in
isolated, endothelium-disrupted pulmonary arteries. E-IH increased both basal and ET-1stimulated DHE fluorescence (Figure 36), and this was prevented by pretreatment with
tiron. The effect of ET-1 to increase O2- levels was unique to E-IH vessels and was not
present in Sham arteries. In addition, tiron had no effect on DHE fluorescence in Sham
arteries.

Specific Aim 4.5 - Assess the role of ROS-dependent PKC activation in enhanced ET-1induced vasoconstriction following E-IH.
Effect of Combined ROS Scavenging and PKC Inhibition on Vasoconstrictor Reactivity to
ET-1
To address whether ROS and PKC signal through a common pathway,
vasoconstrictor and VSM Ca2+ responses to ET-1 were assessed in the during combined
O2- scavenging and PKC inhibition using tiron/Ro 31-8220. Similar to effects of either
treatment

alone,

combined

ROS

scavenging

and

PKC

inhibition

attenuated

vasoconstrictor responses to ET-1 in E-IH but not Sham vessels and normalized
responses between groups (Figure 37). Furthermore, combined treatment with Ro 318220 and tiron did not appear to result in greater inhibition of the vasoconstriction than
either treatment alone. However, treatment with Ro 31-8220 and tiron decreased Ca2+
responses to ET-1 in E-IH (10-8.5-10-7 M) and Sham (10-7.5 M) vessels, similar to effects
of Ro 31-8220 alone.
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Figure 36. Basal and ET-1-stimulated DHE fluorescence in pulmonary arteries
from Sham and E-IH rats in the presence and absence of the superoxide
scavenger tiron (10 mM). (*P<0.05 E-IH vs. Sham; † P<0.05 vs. E-IH +
vehicle; # P<0.05 vs. basal) Data are means ± SE of n= 4-7/group.
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Figure 37. A) Vasoconstrictor and B) VSM [Ca2+]i responses in the presence and
absence of the superoxide scavenger tiron (10 mM) and the PKC inhibitor Ro 318220 (Ro, 10 μM). (*P<0.05 E-IH vs. Sham; #P<0.05 E-IH vs. E-IH + Ro +
tiron; †P<0.05 Sham vs. Sham + Ro + tiron) Data are means ± SE of n= 46/group.
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In the presence of combined ROS scavenging and PKCα/β inhibition,
vasoconstriction to ET-1 was again attenuated in vessels from E-IH rats to the level of
Sham vessels (Figure 38A), without altering Ca2+ responses to ET-1 (Figure 38B). The
effects of combined tiron/myr-PKC treatment were consistent with effects of either drug
alone. Therefore, the effect of these two drugs did not appear to be additive suggesting
that ROS and PKCα/β signal in series to mediated enhanced ET-1 vasoconstrictor
reactivity after E-IH. Sham vessels treated with either the combination of tiron/Ro 318220 or tiron/myr-PKC had significantly larger basal inner diameters than the
corresponding vehicle-treated Sham arteries. However, neither tiron/Ro 31-8220 nor
tiron/myr-PKC altered basal F340/F380 values (Table 8).

Effect of PKCα/β Ιnhibition on Basal and ET-1-Stimulated O2- Levels in Pulmonary
Arteries
To determine whether PKC functions at a point proximal or distal to the site of
agonist-induced ROS generation in E-IH arteries, we evaluated basal and ET-1stimulated DHE fluorescence in both the presence and absence of the PKCα/β inhibitor,
myr-PKC. Interestingly, myr-PKC prevented both the enhanced basal and ET-1-induced
O2- generation in vessels from E-IH rats (Figure 39), suggesting that PKCα/β mediate
both basal and agonist-stimulated ROS production following E-IH.
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Figure 38. A) Vasoconstrictor and B) VSM [Ca2+]i responses in the presence and
absence of the superoxide scavenger tiron (10mM) and the PKCα/β inhibitor
myr-PKC (10 μM). (*P<0.05 E-IH vs. Sham; #P<0.05 E-IH vs. E-IH + myr-PKC
+ tiron) Data are means ± SE of n= 4-6/group.
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Figure 39. Basal and ET-1-stimulated DHE fluorescence in pulmonary arteries
from Sham and E-IH rats in the following treatment with vehicle or the PKCα/β
inhibitor myr-PKC (10 μM). (*P<0.05 E-IH vs. Sham; † P<0.05 vs. E-IH +
vehicle; # P<0.05 vs. basal) Data are means ± SE of n= 5-7/group.
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Summary of Results for Specific Aim 4
•

In vivo treatment with an SOD mimetic prevents E-IH-induced right ventricular
hypertrophy.

•

Increased ET-1-induced vasoconstriction following E-IH is unaffected by inhibitors
of NOX and XO. However, inhibitors of mitochondrial ROS generation prevent
elevated ET-1-induced vasoconstrictor reactivity.

•

E-IH increases both basal and ET-1-stimulated O2- levels in pulmonary arteries.

•

Combined PKCα/β inhibition and ROS scavenging decreases augmented
vasoconstriction to ET-1 in E-IH vessels, to a similar degree as either treatment alone.

•

PKCα/β inhibition prevents ET-1-induced increase in O2- in E-IH arteries.

Conclusions
•

E-IH induces right ventricular hypertrophy via a superoxide-dependent mechanism.
Enhanced pulmonary artery vasoconstrictor reactivity to ET-1 after E-IH is dependent
on mitochondrial O2- but not NOX, XO or H2O2.

•

PKCα/β and

ROS

signal

in

vasoconstriction following E-IH.

series

to

mediate

augmented

ET-1-induced

ET-1-induced O2- production is dependent on

PKCα/β.
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CHAPTER IV

DISCUSSION
Pulmonary hypertension during wakefulness has been reported to occur in 1743% of patients with SA (Arias et al., 2006;Tilkian et al., 1976;Zielinski, 2005) and may
be as severe as 70 mmHg (Ogawa et al., 2006). Furthermore, SA coincident with COPD
results in a 75% occurrence of PH, suggesting that SA exacerbates PH resulting from
COPD (Chaouat et al., 1996;Fletcher et al., 1987;Kessler et al., 1996). Despite growing
recognition of the magnitude of this disorder, the cardiovascular sequelae leading to the
progression of SA-induced PH in humans remains poorly understood. Therefore, we
investigated effects of IH on indices of PH and vasoreactivity using a rat model of SA
that has previously been documented to induce systemic hypertension (Allahdadi et al.,
2005;Kanagy et al., 2001), a common condition in patients with SA.
The major findings of this study are that IH with supplemental CO2 (E-IH) elicits
RV hypertrophy indicative of PH, which is associated with enhanced vasoconstrictor
reactivity but not polycythemia or pulmonary vascular remodeling. In addition, increased
vasoconstrictor reactivity following E-IH is mediated by PKCα/β and mitochondrial O2-,
but not ROK, and PKC acts proximal to O2- generation in pulmonary arteries. Consistent
with a role for O2- in enhanced pulmonary vasoconstrictor reactivity, O2- mediates E-IHinduced RV hypertrophy.
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Specific Aim 1:

Compare effects of E-IH and H-IH on indices of pulmonary

hypertension and vasoconstrictor reactivity.

This aim tested the hypotheses that IH augments pulmonary vasoconstrictor
reactivity and indices of pulmonary hypertension and that supplemental CO2 attenuates
IH-induced polycythemia, arterial remodeling, right ventricular hypertrophy, and
enhanced vasoconstrictor sensitivity. We found that H-IH induced polycythemia and
pulmonary arterial remodeling that was inhibited by supplemental CO2.

However,

despite these inhibitory effects of supplemental CO2, 4 weeks of E-IH exposure produced
a degree of RV hypertrophy similar to that of H-IH and increased vasoconstrictor
reactivity.

Arterial Blood Gases
The level of IH-induced hypoxemia is similar to that reported in human patients
during apneic episodes (Buda et al., 1981). H-IH animals demonstrated a fall in arterial
PCO2 during hypoxia, indicative of hyperventilation in response to hypoxia, but this was
prevented by supplemental CO2. Consistent with these changes in PCO2, arterial pH
remained unchanged in E-IH animals during hypoxia, while H-IH animals became
alkalotic during IH. We have previously shown that 4 wk CH results in a greater PO2 and
reduced pH and PCO2 under both normoxic and hypoxic conditions compared to control
animals, reflecting hyperventilation and acid-base adjustments to CH (Resta & Walker,
1994). However, our results in 4 week E-IH animals suggest that similar acclimation does
not occur with long term E-IH exposure. This is consistent with previous studies of 35
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days of IH exposure in which changes in arterial blood gases are not significantly
different at the beginning of IH exposure versus at the end (Kuwahira et al., 1999).

Right Ventricular Hypertrophy
As reported previously, two week exposure to H-IH resulted in increased right
ventricular hypertrophy in rats (Snow et al., 2008), suggestive of pulmonary
hypertension. While our right ventricular hypertrophy data support the idea that this
model of IH elicits PH, we cannot rule out the possibility that there is a dissociation
between right ventricular hypertrophy and sustained PH. During hypoxic cycling, there
is presumably hypoxic pulmonary vasoconstriction and an associated increase in
pulmonary vascular resistance that occurs at each arterial PO2 nadir.

This periodic

increase in resistance may provide a sufficient stimulus for a compensatory cardiac
hypertrophic response when sustained over a 4 week period, as in the current IH model.
Future studies are planned to measure PAP at rest and during cycling conditions to
determine effects of E-IH on HPV responses and development of sustained PH.
The mechanism by which CO2 reduces IH-mediated RV hypertrophy following 2
weeks of IH exposure remains to be established, however, it is possible that CO2-induced
decreases in ROS are involved. CH elicits PH in newborn rats which is associated with
an increase in oxidant stress assessed by 8-isoprostane content in the lung (Kantores et
al., 2006). Interestingly, exposure of these rats to 10% CO2 during hypoxia reduced
oxidant stress and attenuated CH-induced PH. ROS have additionally been implicated in
contributing to PH based on evidence that there is increased oxidant stress in lungs from
idiopathic pulmonary hypertension patients (Bowers et al., 2004;Cracowski et al., 2001).
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The administration of antioxidants blunts PH (Chen et al., 2001;Hoshikawa et al., 2001)
and this response may be mediated by decreased oxidant-produced pulmonary
vasoconstrictors, such as 8-isoprostane, peroxynitrite, and ET-1 (Jankov et al., 2008).
The effect of CO2 supplementation to prevent hypoxia-induced increases in lung 8isoprostane is additionally associated with decreased lung expression of the potent
endothelium-derived vasoconstrictor peptide, ET-1 (Kantores et al., 2006), suggesting
that multiple mechanisms contribute to the protective effects of CO2 in the hypertensive
pulmonary vasculature.

Polycythemia
CH induces polycythemia via induction of erythropoietin gene expression, and
this mechanism compensates for arterial hypoxemia by increasing the O2 carrying
capacity of the blood.

Polycythemia increases blood viscosity and may increase

pulmonary vascular resistance (Barer et al., 1983) and contribute to PH. However,
studies from our laboratory have shown that polycythemia alone, induced by
administration of recombinant erythropoietin in vivo, is insufficient to cause PH (Walker
et al., 2000).
Other models of IH have also been shown to increase hematocrit (Fagan,
2001;Siques et al., 2006). We, therefore, investigated the possibility that IH increases
hematocrit in our model of SA. As expected, both rat strains exposed to H-IH developed
significant polycythemia. It is likely that IH increases hematocrit via the well known
mechanism of hypoxia-induced increases in HIF-1-dependent gene transcription (Fisher,
2003). HIF-1 drives erythropoietin synthesis in the kidney, and the rise in erythropoietin
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levels stimulates erythropoiesis in the bone marrow. In contrast to effects of H-IH, E-IH
elicited only a modest increase in hematocrit in Sprague Dawley rats and did not increase
hematocrit in Wistar rats, suggesting that CO2 attenuates hypoxia-induced erythropoeisis.
Similarly, supplemental CO2 has been reported to prevent CH-induced polycythemia
(Kantores et al., 2006). Although the mechanism by which this occurs is unknown, it is
possible that CO2 attenuates HIF-1-dependent eryrthropoietin expression. Based on our
present findings that CO2 attenuated both the RV hypertrophy and erythropoietindependent polycythemic responses to H-IH, it is possible that CO2 mediates these
responses through a common mechanism of decreased hypoxia-inducible gene
expression. In fact, recent studies suggest that IH elicits HIF-1α accumulation via ROSdependent mechanisms (Yuan et al., 2008). Therefore, if CO2 decreases oxidative stress
in the lung, this could account for lesser HIF-dependent gene expression.

Pulmonary Arterial Remodeling
Similar to reports of IH causing pulmonary arterial remodeling in mice (Fagan,
2001), the current study indicates that H-IH caused remodeling of small pulmonary
arteries.

This finding is consistent with a previous study in which H-IH caused

pulmonary arterial remodeling, evident by an increase in the number of smooth muscle
α−actin positive vessels, a reduction in luminal diameter and increased arterial wall
thickness in mice (Nisbet et al., 2008). However, in this study by Nisbet et al., the
pulmonary vasculature was not maximally dilated before fixation, which complicates the
interpretation of luminal diameter data. Similar to the effect of CO2 supplementation to
prevent H-IH-induced RV hypertrophy (in Sprague Dawley rats) and polycythemia, the
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present study shows that CO2 prevented IH-induced pulmonary arterial remodeling.
Again, this may be a function of CO2 to decrease oxidative stress and/or HIF-dependent
(Yuan et al., 2008) ET-1 production as previously reported (Jankov et al., 2008).

Pulmonary Vasoconstrictor Reactivity Following IH
IH elicits RV hypertrophy, indicative of PH, and vasoconstriction may contribute
to this response. CH augments pulmonary vasoconstrictor responsiveness to several
other agonists, including UTP, sphingosylphosphorylcholine, prostaglandin F2α,
angiotensin II, and norepinephrine (Jernigan et al., 2004b;McMurtry et al., 1978;Russell
et al., 1990).

Therefore, we addressed effects of IH on pulmonary vasoconstrictor

reactivity. Given that CH increases pulmonary vasoconstrictor reactivity largely through
mechanisms inherent to the VSM (Jernigan et al., 2008), we assessed responses in
endothelium-disrupted arteries. We observed that E-IH increased vasoconstrictor
reactivity to agonists ET-1, UTP, and 5-HT, indicative of a generalized hyper-reactivity
to pulmonary vasoconstrictors. This greater propensity for vasoconstriction was not
associated with a greater Ca2+ response, suggesting that E-IH increases VSM Ca2+
sensitivity. A limitation of studying endothelium-disrupted arteries is the possibility that
IH results in compensatory increases in endothelium-dependent dilation, which may
offset the observed increase in vasoconstrictor reactivity. However, our previous studies
suggest that endothelium-dependent dilation is not altered by IH (Snow et al., 2008).
Similar to our present observations of greater agonist-induced vasoconstriction in arteries
from E-IH rats, Thomas and Wanstall (Thomas & Wanstall, 2003) found that IH
(continuous 10% O2 for 8 hr/day) enhanced vasoconstriction to various agonists
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including U-46619, 5-HT and ET-1 in rat main pulmonary artery rings.

Although

enhanced vasoconstrictor reactivity could be explained by an increase in receptor
expression, the increase in reactivity to multiple agonists argues against this possibility.
It is more likely that intracellular signaling mechanisms, which are commonly stimulated
by various agonists, are increased by E-IH to contribute to increased pulmonary
vasoconstrictor reactivity. Given the observed E-IH-induced RV hypertrophy in the
absence of an obvious fixed component due to pulmonary vascular remodeling, increased
vasoconstrictor reactivity may provide an important contribution to the pulmonary
hypertensive response to IH.

Summary of Aim 1
Findings in Specific Aim 1 suggest that H-IH, but not E-IH, elicits PH in Sprague
Dawley rats, suggesting that eucapnia prevents IH-induced PH in these rats. Such an
effect of supplemental CO2 to attenuate PH has previously been reported in the setting of
CH (Kantores et al., 2006). However, the current study indicates that 4 weeks of E-IH is
a more potent stimulus for the development of PH in Wistar rats.

Therefore, we

performed all experiments in Specific Aims 2-4 in Wistar rats exposed to 4 weeks of EIH. Although E-IH elicited substantial RV hypertrophy, polycythemia and pulmonary
vascular remodeling were minimal or nonexistent, suggesting that vasoconstriction
underlies the development of PH.

Consistent with that possibility, E-IH increased

vasoconstrictor reactivity to multiple agonists. Studies in Specific Aims 2-4 addressed
the VSM signaling mechanisms responsible for this enhanced vasoconstrictor
responsiveness following E-IH.
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Specific Aim 2: Assess the role of ROK in mediating right ventricular hypertrophy
and enhanced agonist-induced pulmonary vasoconstriction following E-IH.

Role of ROK in E-IH-Induced Pulmonary Hypertension
ROK-mediated signaling is increased in pulmonary arteries of patients with
idiopathic PH (Guilluy et al., 2009) and ROK contributes to CH- (Nagaoka et al., 2004)
and monocrotaline-induced PH (Abe et al., 2004;Homma et al., 2008). Therefore, we
investigated the potential role of ROK in mediating IH-induced PH. However, we
observed that in vivo treatment with fasudil did not significantly inhibit the development
of right ventricular hypertrophy. Previous studies have demonstrated that this dose of
fasudil prevents CH-induced (Nagaoka et al., 2006) and monocrotaline-induced PH (Abe
et al., 2004), suggesting that our dose should be efficacious in the current setting. We
conclude that E-IH-induced PH is not mediated by ROK. The reason for the difference
between our findings and those in other models of PH is unclear, but it is apparent that
CH and E-IH evoke divergent signaling mechanisms responsible for the development of
PH.

Role of ROK in Enhanced Vasoconstrictor Reactivity to ET-1 After E-IH
ROK mediates CH-induced pulmonary arterial basal tone (Broughton et al., 2008)
and increased vasoconstrictor reactivity (Jernigan et al., 2004b;Jernigan et al., 2008).
Furthermore, E-IH enhances vasoconstrictor reactivity via a Ca2+ sensitization
mechanism. Therefore, we examined the role of ROK in augmented ET-1-induced
vasoconstrictor reactivity following E-IH. However, in agreement with our finding that
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in vivo fasudil treatment did not prevent RV hypertrophy, we found that inhibition of
ROK with fasudil did not affect vasoconstrictor responses to ET-1 in vessels from either
E-IH or Sham rats. The reported IC50 of fasudil for ROK (~2 μM) (Davies et al., 2000)
and previous studies from our laboratory (Broughton et al., 2008) indicate that 10 μM
fasudil inhibits myogenic constriction of pulmonary arteries, lending support to the
efficacy of fasudil in the current preparation. These data suggest that ROK is not a
mediator of ET-1-induced constriction and that E-IH, in contrast to CH, does not increase
ROK-dependent signaling. The lack of a role for ROK in augmented vasoconstrictor
reactivity is consistent with our finding that E-IH-induced PH is not mediated by ROK.
The differential effect of CH and IH on ROK-dependent vasoconstriction may be related
to contrary effects of IH versus CH on RhoA activity or ROK expression, with IH
presumably not increasing either.

Summary of Aim 2
ROK does not contribute to E-IH-induced RV hypertrophy or to ET-1-induced
pulmonary vasoconstriction in either E-IH or in Sham rats. These findings are surprising
given the importance of ROK in ET-1-induced vasoconstriction (Jernigan et al., 2008)
and the development of PH in other models of PH (Homma et al., 2008;Nagaoka et al.,
2006). Based on these findings, we sought to identify an alternative signaling pathway
that could mediate enhanced vasoconstrictor reactivity and E-IH-induced PH. Thus, the
next aim is focused on the role of PKC in vasoconstrictor reactivity following E-IH.
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Specific Aim 3: Assess the contribution of PKC to increased agonist-mediated
vasoconstriction following E-IH.

Role of PKC in ET-1-Induced Vasoconstriction
Based on the finding that ROK is not involved in augmented vasoconstrictor
reactivity following E-IH, we investigated a potential role for PKC in mediating ET-1induced Ca2+ sensitization. General PKC inhibition decreased vasoconstrictor reactivity
to ET-1 in both Sham and E-IH vessels and normalized responses between groups, while
also decreasing the Ca2+ response to ET-1. These findings support a role for PKC in
increased ET-1-induced vasoconstriction after E-IH and are consistent with a study
indicating that ET-1-induced vasoconstriction is mediated in part by PKC in pulmonary
arteries of pulmonary hypertensive rats (Barman, 2007).

However, the fact that

vasoconstriction was reduced in arteries from Sham animals indicates that PKC is not
only involved in ET-1-induced vasoconstriction following E-IH, but rather it is active in
ET-1-induced vasoconstriction in normotensive animals as well. In addition, the broadspectrum PKC inhibitor Ro 31-8220 decreased the Ca2+ response in both Sham and E-IH
arteries, suggesting that a PKC isoform(s) mediates ET-1-induced increases in VSM
[Ca2+]i. One potential mechanism by which PKC could mediate increases in Ca2+ is via
L-type Ca2+ channel activation (Shimoda et al., 1998;Snow et al., 2009). Therefore, ET1-induced activation of PKC may elicit Ca2+ influx via L channels in arteries from both
Sham and E-IH rats.
Classical PKC isoforms have been shown to contribute to the greater ET-1induced vasoconstriction in pulmonary arteries from fawn-hooded rats (Barman, 2007).
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Consistent with these findings, we saw that PKCα/β inhibition prevented augmented ET1-induced vasoconstriction in vessels from E-IH rats. Attenuated vasoconstriction in EIH vessels in the presence of the PKCα/β inhibitor was associated with a Ca2+ response
that was similar to vehicle-treated E-IH arteries. Furthermore, PKCα/β inhibition had no
effect on responses in Sham arteries, indicating that E-IH evokes a signaling mechanism
involving PKCα/β-dependent VSM Ca2+ sensitization that is not functional in arteries
from Sham rats. We conclude that it is this signaling mechanism that accounts for
enhanced vasoreactivity to ET-1 following E-IH.
Based on evidence that E-IH increases ET-1-induced vasoconstriction via PKCδ
in systemic arteries (Allahdadi et al., 2008b), we hypothesized that PKCδ mediates a
portion of the enhanced pulmonary vasoconstriction to ET-1 in following E-IH.
However, responses to ET-1 were not attenuated by the PKCδ inhibitor rottlerin,
suggesting that PKCδ is either not expressed in PASMCs or is not activated in response
to ET-1.
The finding that general PKC inhibition inhibits both ET-1-induced
vasoconstriction as well as the associated increase in Ca2+ suggests that PKC mediates
this vasoconstriction at least in part by causing increases in [Ca2+]i. However, the finding
that inhibition of PKCα/β and δ does not inhibit ET-1-induced increases in Ca2+ argues
against the contribution of these isoforms to this response. Therefore, another isoenzyme
must contribute to ET-1-induced increases in VSM [Ca2+]i. A good candidate isoform is
PKCε. In pulmonary VSM, it is activated by hypoxia and leads to an increase in [Ca2+]i
(Rathore et al., 2008). Therefore, studies designed to address the role of PKCε in
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enhanced ET-1-induced increases in Ca2+ in Sham and E-IH pulmonary arteries would be
useful.

Effect of E-IH on PKC Expression
We hypothesized that E-IH increases PKCα/β expression in PASMCs to increase
vasoconstrictor reactivity.

We therefore assessed mRNA and protein expression of

PKCα/β using real time PCR and western blot analysis, respectively. In contrast to our
hypothesis, no increases in pulmonary arterial PKCα/β mRNA or protein were detected
following

E-IH,

suggesting

that

enhanced

ET-1-induced

PKCα/β-dependent

vasoconstriction is not due to changes in total cellular expression PKC α, βI or βII. A
limitation to the current approach is the potential contaminating influence of the
endothelium in our samples. The endothelium is a potential source of PKCα/β and could
mask changes in SMC PKC levels. An approach which would ameliorate this problem is
to isolate PASMCs and perform real time PCR on those cell homogenates. In addition,
immunohistochemistry for PKCα/β could address the relative localization of these
proteins to the pulmonary artery endothelium and SMC layers.
It is possible, however, that E-IH increases PKCα/β activity, which may correlate
with the amount of PKCα/β in membrane fraction. Consistent with this possibility,
previous studies in cardiac myocytes (Ding et al., 2004) indicate that IH increases
membrane-associated PKC α/β/ε/δ/γ . Furthermore, ET-1 promotes PKCα membrane
translocation in isolated mesenteric artery SMCs (Nelson et al., 2008) and human
saphenous vein endothelial cells (Ramzy et al., 2006), but this does not necessarily
correlate with increased PKC activity (Ramzy et al., 2006). Future studies are necessary
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to evaluate the effect of E-IH on ET-1-induced PKCα/β membrane localization and
activation. It is possible that ET-1-induced PKC activation is dependent on increased
ROS production following E-IH. The role of ROS in ET-1-induced vasoconstriction will
be addressed in the following specific aim.

Summary of Specific Aim 3
In summary, we have investigated the potential contribution of PKC to enhanced
pulmonary vasoconstrictor reactivity after E-IH. Our results suggest a role for PKCα/β
but not PKCδ in this enhanced vasoconstriction. The increase in PKC-dependent, ET-1induced vasoconstriction does not appear to be mediated by a simple increase in PKCα or
β levels, as pulmonary arterial mRNA and protein expression are unaltered following EIH.

Therefore, it is likely that E-IH increases agonist-induced PKCα/β activity to

mediate the observed effects on pulmonary vasoconstriction.

Specific Aim 4: Determine the contribution of ROS to the development of right
ventricular hypertrophy and enhanced agonist-induced vasoconstriction after E-IH.

Role of ROS in Mediating E-IH-Induced PH
ROS have been implicated in other forms of PH (Nisbet et al., 2009;NozikGrayck et al., 2008) and contribute to enhanced vasoconstrictor sensitivity following CH
(Fike et al., 2008;Jernigan et al., 2008).

We, therefore, sought to determine the

contribution of ROS to E-IH-induced PH. Our finding that in vivo treatment with tempol
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prevented E-IH-induced RV hypertrophy suggests that ROS mediate E-IH-induced PH.
The observed effect of tempol on RV hypertrophy is consistent with a study by Nisbet
and coworkers, in which they found that 8 weeks of IH exposure elicits PH, oxidative
stress and pulmonary vascular remodeling (Nisbet et al., 2008), suggesting that O2mediates IH-induced PH. The effect of tempol to prevent E-IH-induced PH is also
consistent with the idea that E-IH increases pulmonary arterial ROS levels, which could
potentially mediate an increase in vascular remodeling as well as vasoconstriction. While
it is not clear whether this reflects changes in in vivo pulmonary arterial vasoconstriction,
it is possible.
Additional mechanisms could mediate the effect of tempol to prevent E-IHinduced PH. For example, it is possible that in vivo ROS scavenging down regulates the
ET-1 system. In fact, in glomus cells of the carotid body, IH increases ETA receptor
expression, ET-1 release, increased responsiveness to ET-1, all of which are prevented by
in vivo O2- scavenging (Pawar et al., 2009). This is intriguing given that E-IH increases
ETAR expression in whole lung (Allahdadi et al., 2008a). The effect of tempol to prevent
an E-IH-induced increase in ETA receptor expression has not been examined but could
potentially mediate the blunted RV hypertrophy by limiting pulmonary vasoconstriction
and vascular remodeling following E-IH.

Interestingly, HIF-1α accumulation in

response to IH is dependent on ROS generation in PC12 cells (Yuan et al., 2008).
Therefore, tempol treatment may impair E-IH-induced HIF activation and subsequent
increases in gene expression, including ET-1 expression. Diminished HIF activation
could potentially diminish E-IH-induced vasoconstriction. A limitation of our current
study is that we only measured RV hypertrophy and not PAP directly. It is possible that
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ROS scavenging is interfering with the hypertrophic response of the RV and not PH
directly. Future studies will address effects of tempol on E-IH-induced PH. Based on
our finding that ROS contribute to E-IH-induced RV hypertrophy, we next assessed the
role of ROS in enhanced vasoconstrictor reactivity.

Role of ROS in Mediating an Increase in Pulmonary Artery Vasoconstrictor Reactivity
after E-IH
Recent studies from our laboratory have shown that CH increases pulmonary
vasoconstrictor reactivity via ROS-dependent Ca2+ sensitization (Jernigan et al., 2008).
The current study indicates that, similar to CH, E-IH increases O2--dependent
vasoconstrictor reactivity potentially via Ca2+ sensitization because ROS scavenging
prevents the augmented vasoconstrictor reactivity following E-IH without decreasing the
VSM Ca2+ response. The effect of tiron to reduce vasoconstrictor reactivity in E-IH
arteries is consistent with the observed effect of tempol to prevent E-IH-induced RV
hypertrophy. These findings are, further, consistent with studies demonstrating that O2mediates pulmonary VSM Ca2+ sensitization (Jernigan et al., 2008;Knock et al., 2008).
However, whereas O2- activates ROK-dependent Ca2+ sensitization (Jernigan et al.,
2008;Knock et al., 2008), in these studies, our current study suggests that ROS mediate
their vasoconstrictor effect via ROK-independent mechanisms.
Some evidence suggests that H2O2 is a pulmonary vasodilator (Burke & Wolin,
1987).

Specifically, exogenous H2O2 dilates isolated, preconstricted calf pulmonary

arteries (Mohazzab et al., 1996). However, others have shown that endogenous H2O2
constricts pulmonary arteries via increases in VSM [Ca2+]i (Lin et al., 2007). In addition
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to increasing VSM Ca2+, exogenous H2O2 was recently shown to increase RhoA activity
in PASMC (Chi et al., 2009). Another study found that exogenous H2O2 acts as either a
constrictor or dilator and this is dependent upon concentration, with lower concentrations
causing vasorelaxation and higher concentrations potentiating contraction in hypoxiacontracted guinea pig pulmonary arteries (Abdalla & Will, 1995). Despite the evidence
that H2O2 controls the pulmonary arterial contractile state, the lack of an inhibitory effect
of PEG-catalase on constrictions to ET-1 in the current study further supports the finding
that increased vasoconstriction to ET-1 in E-IH vessels is attributable to O2- and not H2O2
production. The lack of a role for H2O2 is additionally consistent with a recent study
(Knock et al., 2008) showing that exogenous O2- constricts small pulmonary arteries
independent of H2O2.

Effect of E-IH on Basal and ET-1-Stimulated ROS Levels
The detection of increased basal and ET-1-stimulated pulmonary artery O2production following E-IH is consistent with our current vasoconstrictor studies in
isolated vessels. Both basal and ET-1-stimulated ROS could contribute to signaling
which promotes PASMC contraction after E-IH.
Although DHE fluorescence is often used as a measure of cellular O2- production,
there are limitations to this approach. First, it is possible that the observed increase in
fluorescence is due to an artifact of arterial constriction as the SMC layers in the plane of
acquisition increase in thickness. However, the lack of effect of ET-1 to increase DHE
fluorescence in Sham arteries, despite a significant constriction provides evidence against
this possibility. Another limitation of this approach is related to the fluorescent products
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detected. In the presence of O2-, DHE is converted to 2-hydroxyethidium and ethidium.
It was initially thought that the primary fluorescent product detected was ethidium
(Bucana et al., 1986). However, more recent studies suggest that 2-hydoxyethidium is
the primary product of the reaction of DHE with O2- but is not optimally detected when
using the standard excitation/emission spectra (F550; F600) (Zhao et al., 2003).

In

addition, it has been suggested that exciting DHE at 396 nm and collecting 579 nm
emissions results in more selective detection of 2-hydroxyethidium and may serve as a
better index of O2- generation (Robinson et al., 2006). Nevertheless, our data provide
direct evidence that our method of detection is sensitive to O2- production because tiron
abolished the effect of ET-1 to increase DHE fluorescence.
O2- levels are a function of not only O2- production but also of the rate of
scavenging by endogenous antioxidant enzymes. It is, therefore, possible that a decrease
in expression or activity of antioxidant enzymes such as SOD occurs following E-IH.
Moreover, IH decreases SOD activity in total lung tissue (Altan et al., 2009). It would be
interesting to address effects of E-IH on expression and activity of cellular SODs.
Potential origins of O2- in the vasculature include NOX, XO and mitochondrial
sources. We, therefore, addressed the potential contribution of these sources to the
augmented vasoconstrictor reactivity following E-IH.

Role of NOX and XO in Agonist-Induced Constriction after E-IH
A major source of O2- in the vasculature is NOX (Griendling et al., 2000), and
NOX2 contributes to IH-induced RV hypertrophy (Nisbet et al., 2008). Based on these
studies, we thought it was likely that E-IH would increase NOX-dependent constriction,

146

given the role of ROS in ET-1-induced vasoconstriction after E-IH. However, inhibition
of NOX with apocynin did not alter constrictions to ET-1 in either group, arguing against
a potential role of NOX1/2.

However, a limitation of using apocynin is its lack of

specificity for NOX. A recent study raised concerns about using apocynin as a NOX
inhibitor, indicating that it is a general antioxidant, rather than a NOX inhibitor
(Heumuller et al., 2008). This would be a concern in our study if we had observed an
effect of apocynin on vasoconstrictor or VSM Ca2+ responses to ET-1, however
regardless of potential antioxidant properties, the lack of effect of apocynin suggests that
NOX1/2 are not involved. Apocynin would not be expected to inhibit NOX4, and thus we
cannot rule out a possible contribution of NOX4 to ET-1-dependent constrictions after EIH. Consistent with this possibility, chronic sustained hypoxia leads to an increase in
mouse pulmonary artery NOX4 mRNA and protein expression (Mittal et al., 2007). In
addition, lungs from IPAH patients have greater NOX4 expression than healthy donor
lungs and isolated human PASMCs exposed to hypoxia demonstrate an increase in
NOX4 mRNA expression. Furthermore, Nesbit et al. found that IH increases lung and
pulmonary artery NOX4 levels.

The role of NOX4 in E-IH-induced increases in

vasoconstrictor reactivity warrants future studies.
XO activity is elevated in patients with idiopathic PH (Spiekermann et al., 2009)
raising the possibility that XO contributes to the development of PH. Consistent with this
possibility, CH increases lung XO activity and vascular XO-derived O2- production in rat
pups (Jankov et al., 2008).

Furthermore, XO inhibition in vivo with allopurinol

attenuates CH-induced vascular remodeling and RV hypertrophy (Jankov et al., 2008).
In addition, hypoxia can acutely increase lung XO activity (Hoshikawa et al., 2001).
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However, in the present study, XO inhibition did not alter vasoconstrictor reactivity to
ET-1 in pulmonary arteries from either Sham or E-IH vessels, indicating that XO does
not contribute to the augmented O2- -dependent vasoconstriction induced by ET-1
following E-IH. Although we did not see an effect of allopurinol, this concentration of
allopurinol is effective in isolated artery preparations (Erdei et al., 2006). We, therefore,
investigated the potential role of mitochondrial ROS generation in this response.

Role of Mitochondrial ROS in Agonist-Induced Constriction after E-IH
Mitochondria produce low levels of ROS under physiological conditions but
under pathological conditions can generate high levels of ROS. ROS production by the
mitochondria occurs predominantly at complexes I and III of the electron transport chain
(Bell et al., 2007;Fato et al., 2008). Acute hypoxia increases mitochondrial ROS to
mediate pulmonary artery vasoconstriction (Desireddi et al., 2009;Waypa et al., 2006).
Therefore, we examined the potential role of mitochondrial ROS generation in ET-1induced vasoconstriction following E-IH by scavenging mitochondrial ROS with the
mitochondrial-targeted nitroxyl compound MITO-CP.

Nitroxyl compounds such as

MITO-CP act as general antioxidants, exhibiting both SOD activity as well as limiting
H2O2-induced damage (Dhanasekaran et al., 2005).

MITO-CP permeates the

mitochondria because of its large lipophilic cation group (Dhanasekaran et al., 2005).
MITO-CP prevented the increased vasoconstrictor reactivity to ET-1 in E-IH vessels,
suggesting an important role for mitochondrial ROS generation in the augmented ET-1induced constriction following E-IH.

Because nitroxyl compounds can impair

fluorescence (Dhanasekaran et al., 2005), one limitation of using MITO-CP when
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measuring fura-2 fluorescence is that it might impair the signal and interfere with
measurement of VSM Ca2+. However, our in situ calibration data indicate that MITO-CP
did not quench fura-2 fluorescence, as measured by F340/F380. In order to strengthen our
conclusion that mitochondrial ROS mediate enhanced vasoconstrictor reactivity, we
additionally assessed responses to ET-1 in the presence of the complex I inhibitor
rotenone.

Consistent with a role for mitochondrial ROS to mediate increased

vasoconstrictor reactivity following E-IH, rotenone also attenuated vasoconstrictor
reactivity to ET-1 in E-IH arteries and normalized responses between groups.
Mitochondria produce both O2- and H2O2. Although acute hypoxia mediates
PASMC contraction via mitochondrial H2O2-dependent increases in VSM Ca2+
(Desireddi et al., 2009), our findings suggest that E-IH increases vasoconstrictor
reactivity via mitochondrial O2-, independent of H2O2, because catalase had no effect on
vasoconstriction or changes in Ca2+. It is generally thought that O2- is fairly membrane
impermeable, whereas H2O2 is more membrane permeable (Michelakis et al.,
2004;Muller et al., 2004).

Therefore, the mechanism by which O2- leaves the

mitochondria to exert its effects on cytosolic components to elicit cell contraction is
unclear, however it has been suggested that mitochondrial anion channels may conduct
O2- (Aon et al., 2004;O'Rourke et al., 2007).
The question of how mitochondrial O2- could mediate increased vasoconstriction
remains unanswered. Complex I produces ROS in the mitochondrial matrix, whereas
complex III generates O2- at the Q0 site, which results in the release of O2- into either the
intermembrane space or the mitochondrial matrix (Muller et al., 2004).

Both

mechanisms of O2- generation would require movement of O2- across one or both
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mitochondrial membranes. The exact site of ROS generation in the mitochondria is
unclear, however it is likely that either complex I or III or both generate the enhanced O2following E-IH, because complex I inhibition in the current study prevented the increased
vasoconstrictor reactivity to ET-1.

In fact, hypoxia-induced increases in ROS are

abolished by genetic or pharmacologic disruption of complex III (Guzy et al., 2005),
lending further support to the idea that complex III may be the main O2- generator in
pulmonary arteries from E-IH animals.
Interestingly, the decrease in vasoconstrictor reactivity in the presence of MITOCP was associated with a diminished Ca2+ response to ET-1 in both groups, indicating
that mitochondrial ROS may contribute to ET-1-induced increases in VSM [Ca2+]i in both
Sham and E-IH vessels. Consistent with this idea, mitochondrial ROS have been shown
to mediate an increase in PASMC [Ca2+]i (Desireddi et al., 2009;Guzy et al., 2005).
However, these findings are at odds with reports that hypoxia, via a decrease in
mitochondrial ROS, increases pulmonary VSM [Ca2+]i (Archer & Michelakis,
2002;Michelakis et al., 2004). On the other hand, the O2- scavenger tiron did not alter
Ca2+ responses to ET-1 in the present study, and the reasons for contrasting effects of
tiron and MITO-CP on VSM Ca2+ are unclear. One possible explanation is that O2signals in cellular microdomains so that scavenging cytosolic ROS may not be sufficient
to inhibit rapid mitochondrial O2- -dependent signaling, which could presumably mediate
an increase in VSM Ca2+. Consistent with ROS production in cellular microdomains,
Zhang et al. showed that the sarcoplasmic reticulum (SR) produce local increases in O2in coronary arterial myocytes (Zhang et al., 2008). In contrast to the effect of MITO-CP
on ET-1-induced increases in Ca2+, the mitochondrial complex I inhibitor rotenone
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exhibited an opposite effect on Ca2+ responses to ET-1. Such an effect of rotenone to
facilitate an increase in VSM Ca2+ is consistent with studies showing that rotenone
mimics acute hypoxia, decreasing mitochondrial ROS, causing a reduction in the cellular
redox potential with inactivates plasmalemmal K+ channels in PASMCs (Archer et al.,
1993).

The resultant membrane depolarization activates L-type VGCCs to mediate

increased PASMC [Ca2+]i (Archer & Michelakis, 2002). If, in the presence of rotenone,
the end effect is enhanced Ca2+ influx through L-type VGCCs, it is difficult to explain the
diminished vasoconstriction associated with this response. Two possible explanations are
that 1) eliminating complex I-dependent ROS decreases a Ca2+ sensitization mechanism,
accounting for attenuated constriction despite augmented Ca2+; 2) rotenone is attenuating
ATP synthesis by inhibiting electron transport. A decrease in ATP levels would be
expected to inhibit Ca2+ extrusion and uptake into the SR via ATP-dependent proteins
(e.g. Na/K ATPase, SERCA), and result in cytosolic Ca2+ accumulation. However, the
achievement of near maximal vasoconstriction in response to ET-1 in the presence of
rotenone argues against an effect of rotenone to inhibit ATP synthesis to a degree
sufficient to limit VSM contractility.
In summary, the effects of both MITO-CP and rotenone to attenuate
vasoconstrictor reactivity to ET-1 following E-IH and normalize responses between
Sham and E-IH arteries lend support to the idea that mitochondrial ROS mediate
vasoconstriction following E-IH.

Future studies will be designed to measure

mitochondrial ROS production and to address the mechanism by which mitochondrial
ROS mediate vasoconstriction.
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Interaction Between PKC and ROS
Our current findings support a primary role for both PKCα/β and ROS in
enhanced pulmonary vasoreactivity to ET-1 following E-IH, although whether these
second messengers signal in parallel pathways or in series to mediate this response is not
apparent from experiments involving PKCα/β inhibition or ROS scavenging alone.
Supporting a series mechanism is evidence that ROS activate PKC signaling in cultured
PC12 cells exposed to IH (Yuan et al., 2008) and in PASMCs exposed to acute hypoxia
(Rathore et al., 2008). We therefore hypothesized that ROS activate PKC to elicit Ca2+
sensitization following agonist stimulation of E-IH vessels. We initially addressed this
hypothesis by evaluating vasoconstrictor responses to ET-1 in the presence of combined
ROS scavenging and PKCα/β inhibition. Our results are consistent with ROS and PKC
signaling through a common pathway, since the combination of tiron and myr-PKC did
not appear to decrease vasoconstriction to ET-1 further in comparison to tiron or myrPKC alone.

To further define whether ROS signal proximally or distally to PKC

activation, we determined effects of selective PKCα/β inhibition on ET-1-induced O2generation in isolated pulmonary arteries from Sham and E-IH rats. However, in contrast
to our hypothesis, we found that PKCα/β inhibition prevented ET-1-mediated increases
in DHE fluorescence in E-IH arteries, indicating that PKCα/β mediate ROS generation
rather than the converse. These findings are consistent with evidence that PKC can
increase ROS (Rathore et al., 2008). In fact, ET-1 stimulates O2- production via PKCα/β
activation in retinal microvessels, however this may be dependent on NOX (Matsuo et
al., 2009). Whereas PKC-dependent activation of NOX represents a major mechanism of
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O2- generation (El Benna et al., 1996;Wolfson et al., 1985), our studies suggest that NOX
does not mediate the augmented ET-1-induced vasoconstriction after E-IH.
Although our results suggest roles for both mitochondrial ROS generation and
PKC to mediate elevated ET-1-induced constriction after E-IH, it is not clear whether
PKC activates mitochondrial ROS generation. However, the role of PKC in modulating
mitochondria in the setting of ischemia reperfusion injury is well established (Budas &
Mochly-Rosen, 2007). Ischemia reperfusion represents a similar disease state to SA
because of the cyclical fall in arterial PO2. Specifically PKCε mediates cardioprotective
effects incurred by ischemic preconditioning (Budas & Mochly-Rosen, 2007), potentially
through its effects on mitochondrial electron transport chain components (Ogbi &
Johnson, 2006), the mitochondrial permeability transition pore (Baines et al., 2002) or
mitochondrial ATP-sensitive K+ channels (Jaburek et al., 2006). Therefore, it is possible
that E-IH promotes a similar interaction between PKC and mitochondrial components
which control ROS production in PASMCs.

Summary of Specific Aim 4
The goal of this Specific Aim was to investigate the role of ROS in E-IH-induced
changes in pulmonary vasoconstrictor reactivity and indices of pulmonary hypertension.
ROS generation contributes to the E-IH-induced PH, therefore we determined the role of
ROS in vasoconstrictor reactivity. We have identified a novel effect of E-IH to increase
O2--dependent, H2O2-independent pulmonary vasoconstrictor reactivity. This increase in
O2- is mediated by mitochondrial ROS generation and not by NOX or XO. Furthermore,
ET-1-induced ROS generation following E-IH is mediated by PKCα/β. Mitochondrial
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ROS generation contributes to augmented vasoconstriction following E-IH, which may
represent a critical component of E-IH-induced PH.

Conclusions
The aim of this dissertation was to examine the mechanism of IH-induced
changes in vasoconstrictor reactivity which may underlie the possible development of
PH. We found that following E-IH, there is evidence for PH that is associated with
modest polycythemia and vascular remodeling, but with a general increase in agonistinduced pulmonary vasoconstrictor reactivity. Elevated vasoconstrictor reactivity to ET1 is mediated by PKCα/β and mitochondrial ROS. Although ROS-dependent PKC
activation following E-IH could elicit VSM Ca2+ sensitization via decreased MLCP
activity, we found that ET-1-induced O2- production is conversely mediated by PKC.
Therefore, the mechanism by which ROS contribute to enhanced ET-1-dependent
vasoconstriction remains to be established. We propose a mechanism (Figure 40) in
which E-IH enhances ET-1-induced PKCα/β activation, which generates mitochondrial
Ο2-. The increased Ο2- production contributes to increased pulmonary VSM cell
contraction and vasoconstriction. The resultant increase in pulmonary vascular resistance
may then contribute to E-IH-induced PH.
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Figure 40. Proposed mechanism for E-IH-induced pulmonary hypertension. E-IH
increases agonist-induced PKCα/β activation which increases mitochondrial O2generation to mediate pulmonary VSM cell contraction. This augmented
pulmonary vasoconstriction may contribute to E-IH-induced PH.
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Clinical Significance
SA causes IH and results in PH, which may lead to right heart failure. Over 18
million adult Americans suffer from SA and 20-40% of those are additionally pulmonary
hypertensive (Sajkov & McEvoy, 2009).

Pulmonary vasoconstriction increases

pulmonary vascular resistance, and thus inhibiting vasoconstriction represents an
important target in the prevention and treatment of SA-induced PH. We have shown that
E-IH augments pulmonary artery vasoconstriction to a variety of agonists, and this
appears to be largely dependent on Ca2+ sensitization mechanisms. Given that E-IH did
not elicit detectable pulmonary arterial remodeling or polycythemia, it seems likely that
the observed increase in vasoconstrictor reactivity may provide an important contribution
to the development of E-IH-induced PH. Furthermore, this increase in vasoconstrictor
reactivity is mediated by ROS and PKC, and ROS contribute to the development of E-IHinduced PH. Consequently, both antioxidants and PKC inhibitors represent potential
targets in the treatment of PH in patients with SA.

Future Directions
Although the results of the current study demonstrate roles for both
mitochondrial O2- and PKCα/β in enhanced ET-1-induced pulmonary vasoconstriction
following E-IH, several questions remain unanswered by the current study.

Future

studies are necessary to establish whether our model of E-IH elicits sustained PH and
whether inhibitory effects of ROS scavenging on E-IH-induced RV hypertrophy occur
secondary to reduced PH. In addition, it is important to determine the effect of E-IH on
pulmonary arterial PKC activity. The lack of increase in pulmonary arterial PKCα/β

156

expression suggests a possible increase in ET-1-induced PKC activity following E-IH.
Consistent with this possibility, Ding and colleagues found that IH increases basal
PKCα/ε and δ in cardiac myocytes only in the membrane fraction (Ding et al., 2004),
suggesting that IH increases basal PKC activity. Therefore, future studies will address
the effect of E-IH on basal and ET-1 stimulated PKCα/β in the membrane and cytosolic
fractions, using western blotting and immunofluorescence approaches.

Another

possibility is that ET receptors and PKC/ROS signaling are more tightly coupled
following E-IH. Caveolin-dependent membrane localization of PKC may be responsible
for such a coupling. In smooth muscle lacking functional caveolin-1, ET-1-induced force
generation is attenuated (Shakirova et al., 2006), suggesting that caveolin-1 mediates ET1-induced contraction. Furthermore, PKC activation is dependent on caveolin in VSM
(Je et al., 2004).

Studies could be designed to determine the effect of disrupting

caveolin-dependent interactions on ET-1-induced vasoconstrictor reactivity following EIH.
In addition, it is unclear what the role of PKC is in mediating agonist-induced
increases in mitochondrial ROS. Studies using the mitochondrial-targeted DHE molecule
MITO-SOX will help us address whether the increase in total cellular ROS is due to
mitochondrial ROS generation and whether PKC inhibition prevents ET-1-induced ROS
generation in E-IH arteries. Perhaps the most difficult question to address is how ET-1induced O2- generation following E-IH mediates PASMC contraction. While greater ET1-induced vasoconstriction in E-IH arteries is not associated with a greater Ca2+ response
and mitochondrial ROS generation attenuates the vasoconstriction, inhibitors of
mitochondrial ROS generation had opposite effects on VSM Ca2+. This result makes the
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role of Ca2+ in this response difficult to address. If, in fact, mitochondrial ROS contribute
to ET-1-induced VSM Ca2+ sensitization in E-IH vessels, the mechanism by which this
occurs is unclear, given that PKC appears to act upstream of ROS generation, and ROK
is not involved in the response. Actin polymerization can mediate an increase in SMC
tension, which may contribute to the observed contractile response (Mehta & Gunst,
1999). Inhibiting actin polymerization with an agent such as cytochalasin D (Mehta &
Gunst, 1999) would allow us to address its role in enhanced ET-1-induced
vasoconstriction following E-IH. Other potential mediators of Ca2+ sensitization are
integrin-linked kinase and zipper interacting protein kinase (Ihara et al., 2007), however
pharmacological inhibitors of these kinases are not readily available. The potential
interaction between ROS and these kinases remains to be determined.
Future studies should also address the role of PKC and ROS-dependent
vasoconstriction in E-IH-induced PH. By acutely administering PKCα/β inhibitors and
O2- scavengers to isolated lungs or whole animals following E-IH and measuring PAP,
the role of these respective components in the development of PH could be addressed.
It is also unclear whether pulmonary arterial ETA/B receptor expression is altered
by E-IH, which might explain the increased vasoconstrictor reactivity to ET-1. However,
our results suggest that an ET-1-stimulated signaling pathway that is mediated by O2- and
PKCα/β is present only following E-IH, and this argues against a simple increase in ET
receptor expression mediating the augmented constriction.

Also, the increase in

vasoconstrictor reactivity to 5-HT and UTP supports a role for a generalized increase in
agonist-induced vasoconstriction, which is unlikely to be due to increases in the
expression of receptors for each of these agonists. Nevertheless, ET receptor expression
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should be addressed by performing real time PCR and western blotting for pulmonary
arterial ETA/B receptor mRNA and protein levels, respectively. However, a more precise
approach would involve isolating PASMCs and evaluating ET receptor expression
because the endothelium would be expected to express ETB receptors and provide a
contaminating influence. Furthermore, the identity of the ET receptor that mediates ET-1induced pulmonary vasoconstriction and whether this is altered by E-IH is unclear and
could be addressed using selective ETA/B receptor antagonists.

It is additionally

important to investigate whether endogenous vasoconstrictor compounds, such as ET-1,
contribute to E-IH-induced PH. The role of ET-1 in mediating E-IH-induced PH via
vasoconstriction could be addressed by acutely administering ET receptor antagonists
such as Bosentan following E-IH exposure and measuring PAP.

If ET-1-induced

vasoconstriction underlies the greater presumed increase in PAP following E-IH, then
acute inhibition of ET receptors would be expected to lower PAP in E-IH animals.
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Appendix A- Abbreviations and Acronyms

Chronic hypoxia- CH
Chronic obstructive pulmonary disease- COPD
Diacylglycerol- DAG
Dihydroethidium- DHE
Endoplasmic reticulum- ER
Endothelial nitric oxide synthase- eNOS
Endothelin-1- ET-1
Eucapnic intermittent hypoxia- E-IH
Hypocapnic intermittent hypoxia- H-IH
Intermittent hypoxia- IH
Myosin light chain- MLC
Myosin light chain kinase- MLCK
Myosin light chain phosphatase- MLCP
NADPH oxidase- NOX
Nitric oxide- NO
Peroxynitrite- ONOOPulmonary artery- PA
Pulmonary artery pressure- PAP
Pulmonary artery smooth muscle cell- PASMC
Pulmonary hypertension- PH
Reactive oxygen species- ROS
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Receptor-operated Ca2+ entry- ROCE
Receptor-operated non-selective cation channels – ROC
Rho kinase- ROK
Right Ventricle- RV
Sarcoplasmic endoplasmic reticulum Ca2+ ATPase- SERCA
Sarcoplasmic reticulum- SR
Sleep apnea- SA
Store- operated Ca2+ entry- SOCE
Superoxide dismutase- SOD
Transient receptor potential cation- TRPC
Vascular smooth muscle- VSM
Voltage-gated Ca2+ channels- VGCC
Xanthine oxidase- XO
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